Biomarker for determining stress level

The use of sialidase activity from fecal samples as a biomarker offers a non-invasive and effective method for diagnosing depression and evaluating stress levels, addressing the limitations of existing methods by providing a simple and objective assessment.

WO2024237332A1PCT designated stage expired Publication Date: 2024-11-21NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE & TECHNOLOGY +1
View PDF 6 Cites 0 Cited by

Patent Information

Application Number
PCT/JP2024/018286
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-18
Filing Date
2024-05-17
Publication Date
2024-11-21

AI Technical Summary

Technical Problem

Current methods for diagnosing depression and evaluating stress levels are invasive, require specialized equipment, and lack objective, quantitative evaluation, making them impractical for widespread clinical use.

Method used

A biomarker based on sialidase activity derived from bacteria in fecal samples, specifically from Clostridium bacteria, is used to determine stress levels and diagnose depression, providing a non-invasive and simple method for objective evaluation.

Benefits of technology

This approach allows for accurate, non-invasive assessment of stress levels and depression diagnosis, reducing the need for invasive procedures and specialized equipment, and providing quick, objective results.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure JPOXMLDOC01-APPB-T000001
    Figure JPOXMLDOC01-APPB-T000001
  • Figure JPOXMLDOC01-APPB-T000002
    Figure JPOXMLDOC01-APPB-T000002
  • Figure JPOXMLDOC01-APPB-T000003
    Figure JPOXMLDOC01-APPB-T000003
Patent Text Reader

Abstract

The present invention addresses the problem of providing: a biomarker for stress level determination in order to determine the stress level of a subject by using a non-invasive and simple method; a detection method for the biomarker; a data collection method including the detection method; and a kit for the stress level determination. This purpose can be achieved by using, as the biomarker, sialidase activity derived from bacteria in a sample acquired from a subject. The sample is preferably feces and / or the subject is preferably a human.
Need to check novelty before this filing date? Find Prior Art

Description

Biomarkers for determining stress levels

[0001] The present invention relates to a biomarker for determining stress level, a method for detecting the biomarker, a data collection method including the detection method, and a kit for determining stress level.

[0002] According to a survey by the Ministry of Health, Labor and Welfare, the lifetime prevalence of depression is estimated to be 3-16%, and the WHO predicts that depression will become the disease that most impairs health by 2030, based on DALY (Disability Adjusted Life Years, an index that represents the burden of disease). The diagnosis and treatment of depression are important issues in modern society. The causes of depression can be complex and are often unknown, but it is known that excessive stress is a trigger.

[0003] Depression has traditionally been diagnosed using the operational judgment method. The operational judgment method applies diagnostic criteria to symptoms and makes a judgment based on the combination of symptoms. Diagnostic criteria include the International Classification of Diseases, 10th Edition (ICD-10) by the WHO and the Diagnostic and Statistical Manual of Mental Disorders, fifth edition (DSM-5) by the American Psychiatric Association. However, there is a lack of testing methods to objectively assess depression, depressive states, stress levels, etc. Numerical diagnostic methods include near-infrared (NIRS), which can objectively test changes in the oxygenation state of cerebral hemoglobin in subjects suspected of depression. However, this has not been adopted as a diagnostic criterion for depression as described above and is currently only used as an auxiliary method for differentiating depression from bipolar disorder. Furthermore, no objective or quantitative evaluation method has been established for stress, which is known to induce depression.

[0004] In order to enable objective evaluation of stress levels and objective diagnosis of depression, progress has been made in the development of markers for determining stress levels, methods for determining stress levels, markers for diagnosing depression, methods for diagnosing depression, etc. For example, as markers for diagnosing depression, those that use the degree of methylation of DNA collected from blood as an index (Patent Document 1), those that use specific genes in blood as markers (Patent Document 2), those that use metabolites in blood as markers (Patent Document 3), etc. have been proposed.

[0005] JP 2019-193578 A JP 2017-000063 A International Publication No. 2017 / 082103

[0006] However, none of these diagnostic markers or diagnostic methods have been clinically applied, and furthermore, there are problems such as the fact that diagnostic sample collection is invasive and requires the intervention of a professional, the diagnostic process requires specialized analytical techniques, the analysis requires expensive and specialized equipment, and it takes time to obtain diagnostic results.The problem that the present invention aims to solve is to provide a biomarker for determining stress level, a method for determining stress level, and a kit for determining stress level, which are non-invasive and simple methods for determining stress level.

[0007] As a result of extensive research, the present inventors have found that the sialidase activity derived from bacteria in a sample obtained from a subject correlates with the stress in the subject, and that the composition of bacterial species in a bacterial population containing sialic acid in the same sample correlates with the stress in the subject, thereby completing the present invention.

[0008] The present invention has the following aspects. [1-1] A biomarker for determining a stress level experienced by a subject, the biomarker being sialidase activity in a sample obtained from the subject. [1-2] The biomarker according to [1-1], which is sialidase activity derived from bacteria in a sample obtained from the subject. [1-3] The biomarker according to [1-2], wherein the sample is feces. [1-4] The biomarker according to any one of [1-1] to [1-3], wherein the subject is a human. [1-5] The biomarker according to any one of [1-1] to [1-4], wherein the bacteria includes bacteria of the class Clostridia. [1-6] A method for detecting a biomarker, comprising detecting the biomarker according to any one of [1-1] to [1-5] in a sample obtained from a subject. [1-7] A method for collecting data for determining a stress level experienced by a subject, the method comprising the detection method according to [1-6]. [1-8] A kit for determining the stress level experienced by a subject, comprising a means for detecting the biomarker according to any one of [1-1] to [1-5]. [1-9] Use of sialidase activity in a sample obtained from a subject as a biomarker for determining the stress level experienced by the subject. [1-10] Use of sialidase activity derived from bacteria in a sample obtained from a subject as a biomarker for determining the stress level experienced by the subject. [1-11] The use according to [1-9] or [1-10], wherein the sample is stool. [1-12] A method for determining the stress level experienced by a subject, comprising the data collection method according to [1-7].

[0009] [2-1] A biomarker for diagnosing depression in a subject, the biomarker being sialidase activity in a sample obtained from the subject. [2-2] The biomarker according to [2-1], which is sialidase activity derived from bacteria in a sample obtained from the subject. [2-3] The biomarker according to [2-2], wherein the sample is feces. [2-4] The biomarker according to any of [2-1] to [2-3], wherein the subject is human. [2-5] The biomarker according to any of [2-1] to [2-4], wherein the bacteria comprises bacteria of the class Clostridia. [2-6] A method for detecting a biomarker, comprising detecting the biomarker according to any of [2-1] to [2-5] in a sample obtained from a subject. [2-7] A method for collecting data for diagnosing depression in a subject, comprising the detection method according to [2-6]. [2-8] A kit for diagnosing depression in a subject, comprising means for detecting the biomarker according to any of [2-1] to [2-5]. [2-9] Use of sialidase activity in a sample obtained from a subject as a biomarker for diagnosing depression in the subject. [2-10] Use of sialidase activity derived from bacteria in a sample obtained from a subject as a biomarker for diagnosing depression in the subject. [2-11] The use according to [2-9] or [2-10], wherein the sample is feces. [2-12] A method for diagnosing depression in a subject, comprising the data collection method according to [2-7]. [2-13] A method for diagnosing depression in a subject, comprising the data collection method according to [2-7].

[0010] [3-1] A biomarker for evaluating the effect of an antidepressant in a subject, the biomarker being sialidase activity in a sample obtained from the subject. [3-2] The biomarker according to [3-1], which is sialidase activity derived from bacteria in a sample obtained from the subject. [3-3] The biomarker according to [3-1] or [3-2], wherein the sample is feces. [3-4] The biomarker according to any of [3-1] to [3-3], wherein the subject is a human. [3-5] The biomarker according to any of [3-1] to [3-4], wherein the bacteria comprises bacteria of the class Clostridia. [3-6] A method for detecting a biomarker, comprising detecting the biomarker according to any of [3-1] to [3-5] in a sample obtained from a subject. [3-7] A method for collecting data for evaluating the effect of an antidepressant in a subject, the method comprising the detection method according to [3-6]. [3-8] A kit for evaluating the effect of an antidepressant in a subject, comprising a means for detecting the biomarker according to any one of [3-1] to [3-5]. [3-9] Use of sialidase activity in a sample obtained from a subject as a biomarker for evaluating the effect of an antidepressant in the subject. [3-10] Use of sialidase activity derived from bacteria in a sample obtained from a subject as a biomarker for evaluating the effect of an antidepressant in the subject. [3-11] The use according to [3-9] or [3-10], wherein the sample is feces. [3-12] A method for evaluating the effect of an antidepressant in a subject, comprising the data collection method according to [3-7].

[0011] [4-1] A biomarker for determining the stress level experienced by a subject, the biomarker being a composition of bacterial species in a bacterial population having sialic acid in a sample obtained from the subject. [4-2] The biomarker according to [4-1], wherein the composition of bacterial species in a bacterial population having sialic acid is the content of bacteria of the class Clostridia in the bacterial population having sialic acid. [4-3] The biomarker according to [4-1] or [4-2], wherein the sample is feces. [4-4] The biomarker according to any of [4-1] to [4-3], wherein the subject is a human. [4-5] A method for detecting a biomarker, comprising detecting the biomarker according to any of [4-1] to [4-4] in a sample obtained from a subject. [4-6] A method for collecting data for determining the stress level experienced by a subject, comprising the detection method according to [4-5]. [4-7] A kit for determining the stress level experienced by a subject, comprising means for detecting the biomarker according to any of [4-1] to [4-4]. [4-8] Use of the composition of bacterial species in a bacterial population having sialic acid in a sample obtained from a subject as a biomarker for determining the stress level experienced by the subject. [4-9] The use according to [4-8], wherein the composition of bacterial species in a bacterial population having sialic acid is the content of bacteria of the class Clostridia in the bacterial population having sialic acid. [4-10] A method for determining the stress level experienced by a subject, comprising the data collection method according to [4-6].

[0012] [5-1] A biomarker for diagnosing depression in a subject, the biomarker being a composition of bacterial species in a bacterial population having sialic acid in a sample obtained from the subject. [5-2] The biomarker according to [5-1], wherein the composition of bacterial species in a bacterial population having sialic acid is the content of bacteria of the class Clostridium in the bacterial population having sialic acid. [5-3] The biomarker according to [5-1] or [5-2], wherein the sample is feces. [5-4] The biomarker according to any of [5-1] to [5-3], wherein the subject is a human. [5-5] A method for detecting a biomarker, comprising detecting the biomarker according to any of [5-1] to [5-4] in a sample obtained from a subject. [5-6] A method for collecting data for diagnosing depression in a subject, comprising the detection method according to [5-5]. [5-7] A kit for diagnosing depression in a subject, comprising means for detecting the biomarker according to any of [5-1] to [5-4]. [5-8] Use of the composition of bacterial species in a bacterial population having sialic acid in a sample obtained from a subject as a biomarker for diagnosing depression in the subject. [5-9] The use according to [5-8], wherein the composition of bacterial species in a bacterial population having sialic acid is the content of bacteria of the class Clostridia in the bacterial population having sialic acid. [5-10] A method for diagnosing depression in a subject, comprising the data collection method according to [5-6]. [5-11] A method for diagnosing depression in a subject, comprising the data collection method according to [5-6].

[0013] [6-1] A biomarker for determining a stress level experienced by a subject, the biomarker being a composition of bacterial species in a bacterial population in a sample obtained from the subject. [6-2] The biomarker according to [6-1], wherein the composition of bacterial species is a composition of bacterial species of the phylum Firmicutes (p_Firmicutes) in the bacterial population.

[0014] [7-1] A biomarker for diagnosing depression in a subject, the biomarker being a composition of bacterial species in a bacterial population in a sample obtained from the subject. [7-2] The biomarker according to [7-1], wherein the composition of bacterial species is a composition of bacterial species of the phylum Firmicutes (p_Firmicutes) in the bacterial population. [7-3] A method for diagnosing depression in a subject, comprising detecting the biomarker according to [7-1] or [7-2] in a sample obtained from the subject.

[0015] According to the present disclosure, it is possible to provide a biomarker for determining a stress level, a method for detecting the biomarker, and a kit for determining a stress level, which are used to determine the stress level of a subject by a non-invasive and simple method. According to the present disclosure, it is possible to provide a biomarker for diagnosing depression, a method for detecting the biomarker, and a kit for diagnosing depression, which are used to diagnose patients with depression by a non-invasive and simple method. Furthermore, it is possible to provide a biomarker for evaluating the effectiveness of an antidepressant by a non-invasive and simple method, a method for detecting the biomarker, and a kit for evaluating the effectiveness of an antidepressant.

[0016] 1 is a diagram showing the results of an analysis (principal coordinate analysis) of the microbial composition in fecal samples from mice in the control group, chronic ultra-mild stress (CUMS) group, and CUMS plus antidepressant administration group in Example 2. 2 is a graph showing the bacterial counts (relative amounts) of each bacterial species in fecal samples from mice in the control group, CUMS group, and CUMS plus antidepressant administration group in Example 2. 3 is a graph showing the amount of DNA barcode corresponding to the sialic acid-binding lectin Sambucus nigra Lectin (Elderberry) bark (SNA) in the control group, CUMS group, and CUMS plus antidepressant administration group in Example 3 (*: p<0.05). 4 is a graph showing the approach time (seconds) to the target mouse in a sociability test in mice in the control group, CUMS group, and CUMS plus antidepressant administration group in Example 4 (*p<0.05). This is a graph showing the correlation between the binding of sialic acid-binding lectin SNA to bacterial cells in fecal samples from mice in the control group, CUMS group, and CUMS + antidepressant-administered group obtained in Example 3, and the approach time (horizontal axis, seconds) to the target mouse in the sociability test for mice in the control group, CUMS group, and CUMS + antidepressant-administered group obtained in Example 4 (R = 0.67, p = 0.0026). 1 is a graph showing the cell counts (relative amounts) of bacteria of the class sialic acid-added Clostridia (c_Clostridia), order Clostridiales (o_Clostridiales), family Erysipelotrichaceae (f_Erysipelotrichaceae), genus Lactobacillus (g_Lactobacillus s_reuteri), genus Ruminococcus (g_Ruminococcus), order Lactobacillales (o_Lactobacillales), and species Erysipelotrichaceae (s_Erysipelotrichaceae) in mice of the control group, CUMS group, and CUMS + antidepressant administration group in Example 5. The left figure is a graph showing the correlation between the time (seconds) that the mouse spent in the center and the number of sialic acid-added Lactobacillus reuteri (g_Lactobacillus s_reuteri) bacterial cells in the open field test in Example 5 (R=0.7, p=0.0014).The figure on the right is a graph showing the correlation between the time (seconds) that mice spent in the center and the cell count of sialic acid-added Clostridiales bacteria in the open field test in Example 5 (R=-0.55, p=0.017). This figure is a graph showing the sialidase activity in fecal samples from mice in the control group, CUMS group, and CUMS + antidepressant administration group in Example 6. This figure is a graph showing the correlation between the immobility time (seconds, horizontal axis) in the forced swimming test (FST) in Example 6 and the sialidase activity (vertical axis) in fecal samples from mice in the control group, CUMS group, and CUMS + antidepressant administration group (R=0.85, p=0.0034). 1 is a graph showing the correlation between the cell count (relative amount) of bacteria of the class Clostridia (c_Clostridia) and sialidase activity in fecal samples from mice in the control group, CUMS group, and CUMS + antidepressant administration group obtained in Example 6 (R=0.88, p=0.004). FIG. 1 is a graph showing the correlation between the cell count (relative amount) of bacteria of the phylum Firmicutes (p_Firmicutes) and sialidase activity in fecal samples from mice in the control group, CUMS group, and CUMS + antidepressant administration group obtained in Example 6 (R=0.83, p=0.011). FIG. 1 is a graph showing sialidase activity in fecal samples from healthy subjects (control) and depressed patients (Depressive) in Example 7.

[0017] An embodiment of the present disclosure is described in detail below. The present disclosure is not limited to the following embodiment and can be implemented with appropriate modifications as long as the effects of the present invention are not impaired. Unless otherwise specified in the embodiments and examples, methods described in standard protocol collections such as J. Sambrook, E. F. Fritsch & T. Maniatis (Ed.), Molecular cloning, a laboratory manual (3rd edition), Cold Spring Harbor Press, Cold Spring Harbor, New York (2001); F. M. Ausubel, R. Brent, R. E. Kingston, D. D. Moore, J. G. Seidman, J. A. Smith, K. Struhl (Ed.), Current Protocols in Molecular Biology, John Wiley & Sons Ltd., or modified or altered methods are used. Furthermore, when using commercially available reagent kits or measurement devices, the accompanying protocols are used unless otherwise specified. The configurations and combinations thereof in each embodiment are merely examples, and additions, omissions, substitutions, and other modifications of configurations are possible as appropriate within the scope of the present disclosure. The present disclosure is not limited by the embodiments, but only by the scope of the claims. Each aspect disclosed in this specification can be combined with any other feature disclosed in this specification. When a specific description of one embodiment also applies to other embodiments, that description may be omitted in other embodiments. In this disclosure, the expression "X to Y" regarding a numerical range means "X or more and Y or less."

[0018] First Embodiment (Stress Level Determination Marker, Sialidase Activity) [Biomarker] The biomarker according to the first embodiment is sialidase activity in a sample obtained from a subject. The biomarker of this embodiment can be used to determine the stress level experienced by the subject.

[0019] (Sialidase Activity) Sialidase (also known as neuraminidase, acylneuraminylhydrolase, or EC 3.2.1.18) is a common enzyme found in animals and many microorganisms. It is a glycohydrolase that cleaves sialic acid linked to the terminal α-ketosyl group from glycoproteins, glycolipids, oligosaccharides, and the like. As used herein, sialidase is not limited by the sialic acid to be cleaved. Sialidases are known to exist in a wide range of organisms, including humans (Lipnicanova et al., "Diversity of sialidases found in the human body—A review," International Journal of Biological Macromolecules, Vol. 148, 1 April 2020, Pages 857-868). For example, sialic acid is a general term for nine-carbon sugar 2-keto-3-deoxynonanoic acids bearing a carboxyl group at carbon 1, and is also a general term for N- and / or O-acyl derivatives with neuraminic acid as a core structure. As used herein, sialic acid encompasses both narrowly and broadly defined sialic acid, including N-acetylneuraminic acid (Neu5Ac), N-glycolylneuraminic acid (Neu5Gc), deaminoneuraminic acid (Kdn), etc. Sialic acid is not limited by its modification, and may be, for example, an O-acetylated form, an O-sulfated form, a lactone form, or a lactam form.

[0020] As used herein, "sialidase activity" may refer to the presence or absence of sialidase activity or the level of sialidase activity. That is, in this embodiment, the presence or absence of sialidase activity or the level of sialidase activity in a sample obtained from a subject can be used to determine the stress level experienced by the subject.

[0021] The origin of the sialidase activity is not limited as long as it is in a sample obtained from a subject. However, it is preferably derived from bacteria in the sample, more preferably from enterobacteria in the sample, and even more preferably from bacteria including bacteria of the class Clostridia (c_Clostridia). Here, enterobacteria include any bacteria that inhabited the intestine of the subject before the sample was obtained from the subject. The bacteria in the sample may be two or more species of bacteria. When the bacteria include bacteria of the class Clostridia (c_Clostridia), the sample may contain two or more species of bacteria belonging to the class Clostridia (c_Clostridia), or it may contain one or more species of bacteria belonging to the class Clostridia (c_Clostridia) and one or more species of bacteria belonging to one or more other classes.

[0022] Stress Levels Stress is defined as changes in physical and mental function that occur when exposed to various physical, environmental, and psychological stimuli or stress. It can be broadly classified into acute stress and chronic stress caused by persistent (chronic) stress. Regarding stress levels, "stressed at a certain level" or "stressed" (or "stressed at a certain level" or "stressed") refers to an individual or subject experiencing at least some changes in physical and mental function due to some stimulus or stress. The "level" of stress may refer to the type or magnitude of the stimulus or stress, or the level of changes in physical and mental function caused by the stimulus or stress. It may be an absolute value or a relative value, and may be "high" or "low" compared to a reference value (reference range), a normal value (normal range), or a standard curve (standard range), "present" or "absent," or a score according to a predetermined scoring system. The level of chronic stress can be assessed by those skilled in the art using well-known methods, such as scoring based on a medical interview or questionnaire. For example, the stress level of a subject can be scored and evaluated using the Simple Occupational Stress Questionnaire (57 items) or the simplified version (23 items) of the Simple Occupational Stress Questionnaire in accordance with the Revised Manual for the Stress Check System (revised February 2021, Ministry of Health, Labour and Welfare) based on the Industrial Safety and Health Act. These surveys score the items "work stressors," "physical and mental stress responses," and "surrounding support," and high-stress individuals can be determined based on any criteria for each of these three items or a combination of these. As used herein, "stressed at a predetermined level," "stressed," and the like refer to a state in which a subject is determined to be a high-stress individual using a method based on arbitrarily determined criteria in the Simple Occupational Stress Questionnaire (57 items) or the simplified version (23 items). "Not experiencing a predetermined level of stress," "not experiencing stress," and the like refer to a state in which a subject is determined not to be a high-stress individual using a similar method.

[0023] (Sample) The sample is not limited to the sample obtained from the subject, but is preferably a sample derived from the intestine of the subject. By using sialidase activity derived from bacteria contained in the intestine-derived sample as a biomarker, it becomes easier to determine the stress level of the subject with high accuracy and / or precision. Examples of intestine-derived samples include feces and intestinal mucosal tissue. Here, feces is not limited to the biological sample derived from the intestine of the subject, and broadly encompasses intestinal contents. For example, it includes both intestinal contents after they have been excreted from the subject's body (so-called feces) and intestinal contents before excretion. However, from the viewpoints of non-invasive sample acquisition and the elimination of the need for professional intervention, the intestinal-derived sample is preferably feces excreted from the subject's body. The region of the intestine from which the intestinal contents are derived is not limited, and may be, for example, the small intestine, including the duodenum, jejunum, and ileum, or the large intestine, including the cecum, appendix, colon, and rectum. Here, the large intestine includes, for example, the ascending colon, transverse colon, descending colon, sigmoid colon, upper rectum, and lower rectum, etc. When the sample is feces, it may be collected and stored according to a method well known to those skilled in the art after excretion from the subject until the detection of sialidase activity, so as to prevent contamination with undesired substances not originally contained in feces and / or to prevent a decrease in sialidase activity in the feces.

[0024] (Subject) The subject refers to an individual whose stress level is to be determined, but is not limited to the extent that a stress level determination is necessary and the biomarker is a living organism that is constantly or temporarily present in the body, and may be, for example, a mammal or other animal. The mammal may be a human or a non-human animal, and the non-human animal species may be, for example, a monkey, a dog, a cat, a horse, a cow, a pig, a sheep, a goat, a rabbit, a guinea pig, a hamster, a mouse, and / or a rat, etc., and is not limited by the use of livestock animals, pet animals, laboratory animals, etc., but is preferably a mammal, and more preferably a human.

[0025] In one embodiment, the biomarker for determining the stress level experienced by a subject according to this embodiment is preferably sialidase activity derived from bacteria in a sample obtained from a human. In one embodiment, the biomarker for determining the stress level experienced by a subject according to this embodiment is more preferably sialidase activity derived from bacteria in feces obtained from a human. In one embodiment, the biomarker for determining the stress level experienced by a subject according to this embodiment is even more preferably sialidase activity derived from bacteria, including bacteria of the class Clostridia (c_Clostridia), in feces obtained from a human.

[0026] [Detection Method] In one embodiment, the detection method is a biomarker detection method for detecting any of the biomarkers described in the above [Biomarker] of this embodiment in a sample obtained from a subject. By the detection method described below, any of the biomarkers described in the above [Biomarker] of this embodiment can be detected in a sample obtained from a subject.

[0027] Here, examples and preferred examples of "sialidase activity," "sample," and "analyte" are as described above in [Biomarker] in this embodiment.

[0028] A sample can be obtained from a subject according to a method known to those skilled in the art. For example, if the sample is feces excreted from the subject, at least a portion of the feces can be obtained using a sterilized instrument or the like. For example, if the sample is intestinal contents before excretion from the subject, the sample can be obtained by placing a container against the subject's anus or by inserting an instrument such as a sterile cotton swab or sterile dropper into the subject's anus and attaching the sample to the instrument. For example, if the sample is intestinal mucosal tissue from the subject, the sample can be obtained by inserting a sterilized instrument into the subject's anus in the same manner as intestinal contents and scraping the intestinal mucosal tissue with the instrument.

[0029] Regarding pretreatment prior to biomarker detection, samples obtained from a subject may be subjected to a pretreatment suitable for detection, or may be subjected to detection without treatment. The pretreatment step for detection can be appropriately selected by those skilled in the art according to well-known methods, depending on the type of sample, the content or percentage of biomarker in the sample, and the like. For example, when the sample is feces or intestinal contents, the solid feces or intestinal contents excreted from the subject may be used for biomarker detection in their solid form, or may be dissolved in a solution or the like to be homogenized, and a portion of the solid may be used for biomarker detection. For example, when the sample is intestinal mucosal tissue, a mucosal tissue fragment obtained from the subject may be used for biomarker detection in its solid form, or may be prepared into fine fragments by homogenization or ultrasonication, and then used for biomarker detection. Furthermore, when sialidase activity is derived from bacteria, a desired bacterial population may be isolated from the sample according to well-known methods and used for biomarker detection.

[0030] The detection of a biomarker is not limited to the detection of sialidase activity, and may include, for example, measuring the presence or absence of sialidase activity or measuring the level of sialidase activity. Considering the accuracy and / or precision of diagnosis, the biomarker detection method according to this embodiment is preferably a method that not only measures the presence or absence of sialidase activity, but also includes measuring the level of sialidase activity. In this specification, the level of a biomarker (level of sialidase activity) is also referred to as the measurement value of the biomarker, and may be any of the presence or absence, absolute value, and relative value of the biomarker in a sample.

[0031] In this embodiment, the level of sialidase activity may be an absolute or relative value of enzyme activity. Here, the level of sialidase activity may be expressed, for example, in "international units," which are commonly used units of enzyme activity (one unit is the amount of enzyme that can convert 1 μmol of substrate in 1 minute at 30° C. in 1 L of sample under optimal conditions).

[0032] Sialidase activity can be detected appropriately according to methods well known to those skilled in the art. For example, a substance that is a reaction substrate for sialidase is used to produce a product obtained by an enzymatic reaction of sialidase in a sample, and the presence or absence of sialidase activity in the sample or the level of sialidase activity in the sample can be determined by measuring the decrease in the amount of reaction substrate and / or the increase in the amount of product. Sialidase activity can also be detected using a commercially available sialidase activity assay kit designed using the above-mentioned mechanism, and the presence or absence of sialidase activity or the level of sialidase activity can be determined according to the attached instructions. An example of such a commercially available kit is a neuraminidase activity assay kit (commercially available from Sigma-Aldrich, etc.).

[0033] Instead of detecting sialidase activity itself, sialidase activity may be detected by detecting a parameter correlated with the absolute or relative value of sialidase activity. The parameter correlated with sialidase activity may be, for example, the amount of sialidase protein, which is thought to correlate with the level of sialidase activity. That is, in one embodiment, the method for detecting a biomarker comprises measuring the amount of sialidase protein in a sample obtained from a subject. The amount of sialidase protein can be measured according to methods well known to those skilled in the art. For example, the amount of sialidase protein may be measured by well-known methods such as direct competitive assay, indirect competitive assay, sandwich assay, or other ELISA (enzyme-linked immunosorbent assay), RIA (radioimmunoassay), flow cytometry, immunochromatography, etc., using an antibody or probe that specifically binds to sialidase.

[0034] Furthermore, a parameter correlated with sialidase activity may be, for example, the level of sialic acid-containing sugar chains. The sugar chain level refers to the absolute or relative amount of sugar chains to which sialic acid is added contained in a sample obtained from a subject. When sialidase activity in a sample increases, the cleavage of sialic acid by sialidase becomes more active. Therefore, the level of sialic acid-containing sugar chains contained in a sample decreases in correlation with an increase in the level of sialidase activity. Here, sugar chains to which sialic acid is added are, for example, cell surface sugar chains to which sialic acid is added in bacteria contained in the sample. The term "sialic acid added" (sialylation, sialic acid modification) means that, in an N-linked sugar chain, sialic acid is bound to position 6 or 3 of non-reducing terminal galactose, and in an O-linked sugar chain, sialic acid is bound to position 6, Core 1 (T), or Core 1 of N-acetylgalactosamine. That is, in one embodiment, the biomarker detection method includes measuring the level of sialic acid-containing glycans in a sample obtained from a subject. The level of sialic acid-containing glycans can be measured according to methods known to those skilled in the art, but may also be quantified using, for example, a specific lectin that binds to sialylated glycans. As a more specific example, the level may be measured using the glycan sequencing (Glycan-seq) method developed by Oinam et al. (Glycan Profiling of the Gut Microbiota by Glycan-seq, ISME Communications, 2022 Jan. 5, 2, Article number: 1, doi.org / 10.1038 / s43705-021-00084-2). According to the above detection method, sample acquisition is non-invasive and does not require professional intervention. This allows for easier detection of biomarkers and results than methods requiring blood sampling or biopsy. For example, the subject may perform the entire process from sample acquisition to biomarker detection and obtain test results. Furthermore, by simply measuring and detecting biomarkers, it is possible to obtain objective and / or quantitative test results.

[0035] [Determination Method] A data collection method according to one embodiment is a data collection method for determining the stress level experienced by a subject, including the detection method described in the above [Detection Method] of this embodiment.

[0036] In one embodiment, a stress level experienced by a subject can be determined based on the data collected by the data collection method, i.e., a method for determining a stress level experienced by a subject according to one embodiment includes the data collection method.

[0037] The sialidase activity, which is a biomarker, can be detected by any of the detection methods described above in [Detection Method] of this embodiment.

[0038] In one embodiment, the data collection method for determining the stress level experienced by a subject may include, before performing any of the detection methods described in the above [Detection Method] of this embodiment on samples obtained from one or more individuals who have experienced a predetermined level of stress, performing a biomarker detection method according to the above [Detection Method] of this embodiment on samples obtained from the subject, and obtaining reference values ​​of the biomarkers based on the measured values ​​of the biomarkers in the individuals who have experienced the predetermined level of stress. In another embodiment, the data collection method for determining the stress level experienced by a subject may include, before performing any of the detection methods described in the above [Detection Method] of this embodiment on samples obtained from the subject, performing a biomarker detection method according to the above [Detection Method] of this embodiment on samples obtained from one or more individuals who have experienced a predetermined level of stress and one or more individuals who have not experienced the predetermined level of stress, and obtaining reference values ​​of the biomarkers in individuals who have experienced the predetermined level of stress and reference values ​​(normal values) of the biomarkers in individuals who have not experienced the predetermined level of stress. According to these methods, if the measured value of a biomarker in a sample obtained from a subject is the same as the reference value of the biomarker in an individual experiencing a predetermined level of stress, the subject may be determined to have experienced or be experiencing the predetermined level of stress, or to be highly likely to have experienced the predetermined level of stress, based on the data. Alternatively, if the measured value of a biomarker in a sample obtained from a subject is different from the reference value of the biomarker in an individual experiencing a predetermined level of stress, the subject may be determined to have not experienced or be highly likely to have experienced the predetermined level of stress, based on the data. Furthermore, if the measured value of a biomarker in a sample obtained from a subject is different from the normal value, the subject may be determined to have experienced or be experiencing the predetermined level of stress, or to be highly likely to have experienced the predetermined level of stress, based on the data.Alternatively, if the measured value of the biomarker in a sample obtained from a subject is the same as the normal value, the data may be used to determine that the subject is not experiencing a predetermined level of stress, or that the subject is likely not experiencing a predetermined level of stress. In one embodiment, if the measured value of the biomarker in a sample obtained from a subject is elevated compared to the normal value, the data may be used to determine that the subject has experienced or is experiencing a predetermined level of stress, or that the subject is likely experiencing or is experiencing a predetermined level of stress. This is because sialidase activity in a sample obtained from a stressed individual is, or tends to be, higher than sialidase activity in a sample obtained from a non-stressed individual.

[0039] In another embodiment, a method for collecting data to determine a stress level experienced by a subject may include, before performing any of the detection methods described in the above "Detection Method" of this embodiment on a sample obtained from the subject, performing the biomarker detection method according to the above "Detection Method" of this embodiment on samples obtained from multiple individuals or multiple groups of individuals each experiencing different levels of stress, and establishing a standard curve showing the relationship between stress level and biomarker measurement values ​​based on the biomarker measurement values ​​in the individuals or groups of individuals experiencing different levels of stress. According to this method, if the biomarker measurement value in the sample obtained from the subject is the same as any point on the standard curve, the subject may be determined to have experienced or be experiencing a level of stress corresponding to that point, or to be likely to have experienced a predetermined level of stress, based on the data. If the biomarker measurement value in the sample obtained from the subject is different from any point on the standard curve, the subject may be determined to have not experienced a level of stress corresponding to any point on the standard curve, or to be likely to have not experienced a level of stress corresponding to any point on the standard curve, based on the data.

[0040] In another embodiment, a data collection method for determining a stress level experienced by a subject may include performing any of the detection methods described in the above "Detection Method" in this embodiment on multiple samples obtained over time from the same subject. According to this method, if the measured value of a biomarker in a sample obtained from the subject shows a change at a certain time point compared to a previous time point, the subject may be determined to have experienced or be experiencing a predetermined level of stress, or may be determined to have experienced or be likely to have experienced a predetermined level of stress, based on the data. For example, this method can be used to determine and monitor the stress level experienced or being experienced by a subject through periodic health checkups, etc. In one embodiment, if the measured value of a biomarker in a sample obtained from the subject shows an increase at a certain time point compared to a previous time point, the subject may be determined to have experienced or be experiencing a predetermined level of stress, or may be determined to have experienced or be likely to have experienced a predetermined level of stress, based on the data. This is because sialidase activity in a sample obtained from a stressed individual is, or tends to be, higher than sialidase activity in a sample obtained from a non-stressed individual.

[0041] In one embodiment, any of the above determinations may be used to determine the level of stress experienced by the subject.

[0042] Here, the reference value, normal value, or standard curve may be set based on the average or median value of biomarker measurements in samples obtained from individuals of the same group or from the same individual over time, or may be an arbitrarily set reference range, normal range, or standard range based on biomarker measurements. Alternatively, the reference value, normal value, or standard curve may be determined by a person skilled in the art as a value that can determine the stress level of a subject with the desired accuracy and / or precision based on biomarker measurements in samples obtained from individuals of the same group or from the same individual over time. Furthermore, a measurement value of a biomarker in a sample obtained from a subject being the same as a reference value, normal value, or any point on a standard curve may mean, for example, that there is no significant difference from the reference value or normal value using any statistical processing. A measurement value of a biomarker in a sample obtained from a subject that is different from a reference value, normal value, or point on a standard curve may mean, for example, that there is a significant difference from the reference value, normal value, or point on a standard curve using any statistical processing. The measurement value of a biomarker in a sample obtained from a subject being elevated compared to a reference value means, for example, that the measurement value of the biomarker in the sample obtained from the subject is significantly elevated compared to the reference value by any statistical processing. The statistical processing method can be appropriately selected by those skilled in the art according to well-known methods.

[0043] In one embodiment, the reference value may be 150%, 200%, 250%, 300%, 350%, 400%, 450%, or 500% or more of the normal value, and a value that allows a subject to determine the stress level experienced by the subject with the desired accuracy and / or precision may be appropriately determined by a person skilled in the art.

[0044] In one embodiment, the above-described data collection method or the method for determining the stress level experienced by a subject based on the data collection method can also be implemented in combination with other data collection methods for determining the stress level experienced by a subject or other methods for determining the stress level experienced by a subject.

[0045] According to the above-described determination method, sample acquisition is non-invasive and does not require the intervention of a professional. Compared to methods requiring blood sampling or biopsy, biomarkers can be detected and results obtained more easily. For example, the subject himself or herself can perform the entire process from sample acquisition to biomarker detection and obtain the determination results. Furthermore, by simply measuring and detecting biomarkers, objective and / or quantitative determination results can be obtained.

[0046] [Kit] In one embodiment, the kit is a kit for determining the stress level experienced by a subject, comprising means for detecting any of the biomarkers described above in [Biomarkers] of this embodiment.

[0047] In one embodiment, the kit is a kit for carrying out the detection method described above in "Detection method" of this embodiment.

[0048] In one embodiment, the kit may include means for detecting the biomarker, such as a reaction substrate for sialidase, a reagent for detecting a decrease in the reaction substrate / an increase in the product, a positive control reagent for demonstrating that the detection step is functioning, and / or a storage solution for storing a sample obtained from a test subject for sialidase until the detection method is performed, and / or an instruction manual for how to use the kit. Here, the reaction substrate may be provided in a state attached to a container, a chip, etc.

[0049] In one embodiment, the kit may include or be provided with a detection device necessary for detection.

[0050] In one embodiment, at least a portion of the kit may be provided in a state in which it is mounted in a toilet bowl, which facilitates utilization of sialidase activity in feces excreted by a subject for health management.

[0051] According to the above kit, sample acquisition is non-invasive and does not require the intervention of a professional. Compared to methods requiring blood sampling or biopsy, biomarker detection and results can be obtained more easily. For example, the subject himself can perform the entire process from sample acquisition to biomarker detection and obtain the determination results. Furthermore, by simply measuring and detecting biomarkers, objective and / or quantitative determination results can be obtained.

[0052] Second Embodiment (Marker for Diagnosing Depression, Sialidase Activity) [Biomarker] A biomarker according to the second embodiment is sialidase activity in a sample obtained from a subject. The biomarker of this embodiment can be used to diagnose depression in a subject.

[0053] Since stress is known to be a trigger for depression, the sialidase activity in a sample obtained from a subject, which is a biomarker according to the first embodiment, can be used to diagnose depression in the subject.

[0054] (Depression) As used herein, the term "depression" broadly encompasses not only disorders that meet the diagnostic criteria for major depressive disorder according to the WHO International Classification of Diseases, 10th Edition (ICD-10) or the American Psychiatric Association's Diagnostic and Statistical Manual of Mental Disorders, fifth edition (DSM-5) but also various mood disorders and symptoms, as well as adjustment disorders, to the extent that they present with at least a temporary depressive state. It is not limited by the duration of onset or symptom presentation, its severity, and / or its cause (e.g., genetic and external stress, as well as diseases other than psychiatric disorders, such as infectious diseases, neoplastic diseases, and neurological diseases). Examples of the various mood disorders presenting with at least a temporary depressive state include depressive mood disorder, bipolar mood disorder, and the like. In addition to major depression, depressive mood disorders include depression not otherwise specified (NOS), dysthymia (persistent depressive disorder), and the like. Examples of bipolar mood disorders include bipolar I disorder, bipolar II disorder, and bipolar disorder not otherwise specified (NOS). From the viewpoint of diagnosing depression in a subject with higher accuracy and / or precision, the disease to be diagnosed is preferably a depressive mood disorder (including major depression, NOS depression, and dysthymia) or an adjustment disorder, and more preferably major depression, NOS depression, or an adjustment disorder. As long as the mood disorder is one that presents at least temporarily with a depressive state, the subject may exhibit any of the symptoms observed in anxiety disorders, sleep disorders, eating disorders, etc., and the subject may also suffer from a disease other than a psychiatric disorder, such as an infectious disease, a neoplastic disease, or a neurological disease.

[0055] Furthermore, in this specification, the term "suffering from depression" and the like encompasses not only the presence of depression but also a high possibility of suffering from depression. Furthermore, in this specification, the terms "diagnosis of depression," "diagnosing depression," and "depression diagnosis" and the like encompass not only determining whether or not a person has depression, but also determining whether or not a person is highly likely to have depression.

[0056] As used herein, the terms "healthy" and "healthy individual" in the context of "depression" refer to individuals who have not been diagnosed with depression or who are unlikely to suffer from depression. This also includes individuals who suffer from diseases other than depression.

[0057] (Sialidase activity) Examples and preferred examples of "sialidase activity" are as described in the section "Sialidase activity" in [Biomarker] of the first embodiment.

[0058] (Sample) Examples and preferred examples of the "sample" are as described in the "Sample" section of [Biomarker] in the first embodiment.

[0059] (Subject) The term "subject" refers to an individual who is to be diagnosed with depression. Except for the subject who needs to be diagnosed with depression, examples and preferred examples of the subject are as described in the "Subject" section of [Biomarker] in the first embodiment.

[0060] [Detection Method] The detection method in one embodiment is a biomarker detection method in which any of the biomarkers described above in [Biomarker] of this embodiment is detected in a sample obtained from a subject.

[0061] Here, examples and preferred examples of "sialidase activity," "sample," and "analyte" are as described above in [Biomarker] in this embodiment.

[0062] In this embodiment, the acquisition of a sample from a subject, the pretreatment prior to the detection of a biomarker, and the detection of a biomarker are as described in the "Detection method" of the first embodiment.

[0063] According to the above detection method, sample acquisition is non-invasive and does not require the intervention of a professional, and biomarker detection and results can be obtained more easily than methods requiring blood sampling or biopsy. For example, the subject himself can perform everything from sample acquisition to biomarker detection and obtain test results. Furthermore, by simply measuring and detecting biomarkers, objective and / or quantitative test results can be obtained.

[0064] [Diagnostic Method] A data collection method according to one embodiment is a data collection method for diagnosing depression in a subject, which includes the detection method described in the above [Detection Method] of this embodiment.

[0065] The sialidase activity, which is a biomarker, can be detected by any of the detection methods described above in [Detection Method] of this embodiment.

[0066] In one embodiment, the method for collecting data for diagnosing depression in a subject may include, before performing any of the detection methods described in the above [Detection Method] of this embodiment on a sample obtained from the subject, performing the biomarker detection method according to the above [Detection Method] of this embodiment on samples obtained from one or more depressed patients, and obtaining reference values ​​of the biomarkers based on the measured values ​​of the biomarkers in the depressed patients. In another embodiment, the method for collecting data for diagnosing depression in a subject may include, before performing any of the detection methods described in the above [Detection Method] of this embodiment on samples obtained from the subject, performing the biomarker detection method according to the above [Detection Method] of this embodiment on samples obtained from one or more depressed patients and one or more healthy subjects, and obtaining reference values ​​of the biomarkers in depressed patients and reference values ​​(normal values) of the biomarkers in healthy subjects. According to these methods, if the measured value of a biomarker in a sample obtained from a subject is the same as the reference value of the biomarker in depressed patients, the subject may be determined to have depression or to have a high probability of having depression based on the data. Alternatively, if the measured value of a biomarker in a sample obtained from a subject is different from the reference value of the biomarker in depressed patients, the subject may be determined to not have depression or to have a low probability of having depression based on the data. Furthermore, if the measured value of a biomarker in a sample obtained from a subject is different from the normal value, the subject may be determined to have depression or to have a high probability of having depression based on the data. Alternatively, if the measured value of a biomarker in a sample obtained from a subject is the same as the normal value, the subject may be determined to not have depression or to have a low probability of having depression based on the data.In one embodiment, when the measured value of the biomarker in a sample obtained from a subject is elevated compared to the normal value, the subject may be determined to be suffering from depression or to be highly likely to be suffering from depression based on the data, because the sialidase activity in a sample obtained from a depressed patient is higher or tends to be higher than the sialidase activity in a sample obtained from a healthy subject.

[0067] In another embodiment, a method for collecting data for diagnosing depression in a subject may include performing any of the detection methods described in the above "Detection Method" in this embodiment on multiple samples obtained over time from the same subject. According to this method, if the measured value of a biomarker in a sample obtained from the subject shows a change at a certain time point compared to previous values, the subject may be determined to have depression or to have a high probability of having depression based on the data. For example, this method can be used to monitor the subject's depression through periodic health checkups, etc. In one embodiment, if the measured value of a biomarker in a sample obtained from the subject shows an increase at a certain time point compared to previous values, the subject may be determined to have depression or to have a high probability of having depression based on the data. This is because sialidase activity in samples obtained from depressed patients is, or tends to be, higher than sialidase activity in samples obtained from healthy individuals.

[0068] In one embodiment, the subject can be diagnosed with depression by any of the above determinations.

[0069] Here, the reference value or normal value may be set based on the average or median value of the biomarker measurements in samples obtained from individuals of the same group or from the same individual over time, or may be a reference range or normal range arbitrarily set based on the biomarker measurements. Alternatively, the reference value or normal value may be a value that can determine the presence of depression in a subject with the desired accuracy and / or precision based on the biomarker measurements in samples obtained from individuals of the same group or from the same individual over time. Furthermore, the measurement value of a biomarker in a sample obtained from a subject being the same as the reference value or normal value may mean, for example, that there is no significant difference from the reference value or normal value as determined by any statistical processing. The measurement value of a biomarker in a sample obtained from a subject being different from the reference value or normal value may mean, for example, that there is a significant difference from the reference value or normal value as determined by any statistical processing. The measurement value of a biomarker in a sample obtained from a subject being elevated compared to the reference value may mean, for example, that the measurement value of a biomarker in a sample obtained from a subject is significantly elevated compared to the reference value as determined by any statistical processing. The statistical processing method can be appropriately selected according to well-known methods by those skilled in the art.

[0070] In one embodiment, the reference value may be 150%, 200%, 250%, 300%, 350%, 400%, 450%, or 500% or more of the normal value, and a value that allows a subject to be determined to have depression with a desired accuracy and / or precision may be appropriately determined by a person skilled in the art.

[0071] In one embodiment, the above-described data collection method or the method for diagnosing the onset of depression based on the data collection method can also be performed in combination with other data collection methods for diagnosing depression or other methods for diagnosing depression.

[0072] According to the above evaluation method, sample acquisition is non-invasive and does not require the intervention of a professional. Compared to methods requiring blood sampling or biopsy, biomarker detection and results can be obtained more easily. For example, the subject himself or herself can perform the entire process from sample acquisition to biomarker detection and obtain diagnostic results. Furthermore, by simply measuring and detecting biomarkers, objective and / or quantitative diagnostic results can be obtained.

[0073] Third Embodiment (Sialidase Activity, Marker for Evaluating the Effect of Antidepressants) [Biomarker] The biomarker according to the third embodiment is sialidase activity in a sample obtained from a subject. The biomarker of this embodiment can be used to evaluate the effect of an antidepressant in a subject.

[0074] As explained in the second embodiment, sialidase activity in a sample obtained from a subject can be used as a biomarker for diagnosing depression in the subject. Therefore, by using sialidase activity as a biomarker, it is possible to determine whether the depression of a subject has improved after administration of an antidepressant, i.e., to evaluate the effectiveness of the antidepressant in the subject.

[0075] (Sialidase activity) Examples and preferred examples of "sialidase activity" are as described in the section "Sialidase activity" in [Biomarker] of the first embodiment.

[0076] (Antidepressants) As used herein, the term "antidepressants" encompasses approved and unapproved medications and therapies used to treat depression in Japan and other foreign countries. Examples include selective serotonin reuptake inhibitors (SSRIs), serotonin-noradrenaline reuptake inhibitors (SNRIs), electroconvulsive therapy, and / or transcranial magnetic stimulation. Examples of selective serotonin reuptake inhibitors include escitalopram, sertraline, and paroxetine, and examples of serotonin-noradrenaline reuptake inhibitors include imipramine and venlafaxine.

[0077] (Sample) Examples and preferred examples of the "sample" are as described in the "Sample" section of [Biomarker] in the first embodiment.

[0078] (Subject) "Subject" refers to an individual who is the subject of evaluation of the effects of an antidepressant. Examples and preferred examples are as described in the "Subject" section of [Biomarker] in the first embodiment, except that the subject is a subject for whom evaluation of the effects of an antidepressant is necessary. Since the biomarker according to this embodiment is a biomarker for evaluating the effects of an antidepressant, the subject is preferably a depressed patient or an individual suspected of suffering from depression. An individual suspected of suffering from depression may be an individual who has experienced or is experiencing a predetermined level of stress.

[0079] [Detection Method] The detection method in one embodiment is a biomarker detection method in which any of the biomarkers described above in [Biomarker] of this embodiment is detected in a sample obtained from a subject.

[0080] Here, examples and preferred examples of "sialidase activity," "sample," and "analyte" are as described above in [Biomarker] in this embodiment.

[0081] In this embodiment, the acquisition of a sample from a subject, the pretreatment prior to the detection of a biomarker, and the detection of a biomarker are as described in the "Detection method" of the first embodiment.

[0082] According to the above detection method, sample acquisition is non-invasive and does not require the intervention of a professional, and biomarker detection and results can be obtained more easily than methods requiring blood sampling or biopsy. For example, the subject himself can perform everything from sample acquisition to biomarker detection and obtain test results. Furthermore, by simply measuring and detecting biomarkers, objective and / or quantitative test results can be obtained.

[0083] [Evaluation Method] A data collection method according to one embodiment is a data collection method for evaluating the effect of an antidepressant drug in a subject, which includes the detection method described in the above [Detection Method] of this embodiment.

[0084] In one embodiment, the effect of an antidepressant in a subject can be evaluated based on the data collected by the data collection method, i.e., a method for evaluating the effect of an antidepressant in a subject according to one embodiment includes the data collection method.

[0085] The sialidase activity, which is a biomarker, can be detected by any of the detection methods described above in [Detection Method] of this embodiment.

[0086] In one embodiment, the method for collecting data to evaluate the effect of an antidepressant in a subject may include, before performing the above-mentioned [Detection Method] of this embodiment on a sample obtained from the subject, performing the biomarker detection method according to the above-mentioned [Detection Method] of this embodiment on a sample obtained from one or more depressed patients who have responded to the antidepressant (including former depressed patients who have recovered from treatment) or healthy subjects, to obtain reference values ​​of the biomarkers in the depressed patients who have responded to the antidepressant. In another embodiment, the method for collecting data to evaluate the effect of an antidepressant in a subject may include, before performing any of the detection methods described in the above-mentioned [Detection Method] of this embodiment on a sample obtained from the subject, performing the biomarker detection method according to the above-mentioned [Detection Method] of this embodiment on a sample obtained from one or more depressed patients who have not responded to the antidepressant or who have not been treated with the antidepressant. In another embodiment, a method for collecting data to evaluate the effect of an antidepressant in a subject may include, before performing any of the detection methods described in the above [Detection Method] of this embodiment on a sample obtained from the subject, performing a biomarker detection method according to the above [Detection Method] of this embodiment on samples obtained from one or more depressed patients who have benefited from the antidepressant (including former depressed patients who have recovered from treatment) or healthy subjects, and one or more depressed patients who have not benefited from the antidepressant or who have not been treated with the antidepressant, to obtain a reference value of the biomarker in the depressed patients who have benefited from the antidepressant or the healthy subjects (first reference value) and a reference value in the depressed patients who have not benefited from the antidepressant or the depressed patients who have not been treated with the antidepressant (second reference value).According to these methods, if the measured value of a biomarker in a sample obtained from a subject is the same as the reference value of the biomarker in depressed patients or healthy subjects who have benefited from an antidepressant, the subject may be determined to have benefited from the antidepressant or may be determined to have a high probability of benefiting from the antidepressant based on the data. Alternatively, if the measured value of a biomarker in a sample obtained from a subject is different from the reference value of the biomarker in depressed patients or healthy subjects who have benefited from the antidepressant, the subject may be determined to have not benefited from the antidepressant or may be determined to have a high probability of benefiting from the antidepressant based on the data. Furthermore, if the measured value of a biomarker in a sample obtained from a subject is different from the reference value of the biomarker in depressed patients who have not benefited from the antidepressant or in depressed patients who have not been treated with the antidepressant, the subject may be determined to have benefited from the antidepressant or may be determined to have a high probability of benefiting from the antidepressant based on the data. Alternatively, if the measured value of the biomarker in a sample obtained from a subject is the same as the reference value of the biomarker in depressed patients who have not responded to antidepressants or in depressed patients who have not been treated with the antidepressants, it may be determined based on the data that the subject has not responded to the antidepressant, or that it is highly likely that the antidepressant has not responded to the subject. In one embodiment, if the measured value of the biomarker in a sample obtained from a subject is lower than the reference value of the biomarker in depressed patients who have not responded to antidepressants or in depressed patients who have not been treated with the antidepressant, it may be determined based on the data that the subject has responded to the antidepressant, or that it is highly likely that the antidepressant has responded to the subject. This is because the sialidase activity in samples obtained from depressed patients or healthy individuals who have responded to antidepressants is lower, or tends to be lower, than the sialidase activity in samples obtained from depressed patients who have not responded to antidepressants or in depressed patients who have not been treated with the antidepressant.

[0087] In another embodiment, a data collection method for evaluating the effectiveness of an antidepressant in a subject may include performing the above-described "detection method" of this embodiment on multiple samples obtained over time from the same subject. According to this method, if the measured value of a biomarker in a sample obtained from the subject shows a change at a certain time point compared to a previous time point, it may be determined based on the data that the subject has benefited from the antidepressant, or that the subject is likely to have benefited from the antidepressant. By periodically monitoring a patient with depression being treated with an antidepressant using this method, it is possible to evaluate the effectiveness of the antidepressant and / or evaluate the improvement of depression. In one embodiment, if the measured value of a biomarker in a sample obtained from the subject shows a decrease at a certain time point compared to a previous time point, it may be determined based on the data that the subject has benefited from the antidepressant, or that the antidepressant is likely to have benefited from the antidepressant, or that the depression has improved, or that the antidepressant is likely to have improved from the depression. In one embodiment, if the measured value of a biomarker in a sample obtained from a subject is elevated at a certain time point compared to previous times, it may be determined based on the data that the effect of the antidepressant in the subject has decreased, or is likely to have decreased, or that the depression has worsened, or is likely to have worsened. This is because the sialidase activity in a sample obtained from a depressed patient who has benefited from an antidepressant or a healthy subject is lower, or tends to be lower, than the sialidase activity in a sample obtained from a depressed patient who has not benefited from an antidepressant or a depressed patient who has not been treated with the antidepressant.

[0088] In one embodiment, any of the above assessments can be used to assess the effectiveness of an antidepressant in a subject.

[0089] Here, the reference value may be the average or median value of the biomarker measurements in samples obtained from the same group of subjects or from the same subject over time, or may be a reference range or normal range arbitrarily established based on the biomarker measurements. Alternatively, the reference value or normal value may be a value that enables the efficacy of an antidepressant drug in a subject to be determined with the desired accuracy and / or precision by a person skilled in the art based on the biomarker measurements in samples obtained from the same group of subjects or from the same subject over time. Furthermore, the measurement value of a biomarker in a sample obtained from a subject being the same as the reference value may mean, for example, that there is no significant difference from the reference value or normal value as determined by any statistical processing. The measurement value of a biomarker in a sample obtained from a subject being different from the reference value may mean, for example, that there is a significant difference from the reference value as determined by any statistical processing. The measurement value of a biomarker in a sample obtained from a subject being elevated compared to the reference value may mean, for example, that the measurement value of a biomarker in a sample obtained from a subject is significantly elevated compared to the reference value as determined by any statistical processing. Furthermore, the phrase "a measured value of a biomarker in a sample obtained from a subject is decreased compared to a reference value" means, for example, that the measured value of the biomarker in the sample obtained from the subject is significantly decreased compared to the reference value by any statistical processing. The statistical processing method can be appropriately selected by those skilled in the art according to well-known methods.

[0090] In one embodiment, the data collection method described above or the method for evaluating the effectiveness of an antidepressant based on the data collection method can also be performed in combination with other data collection methods for evaluating the effectiveness of an antidepressant or other methods for evaluating the effectiveness of an antidepressant.

[0091] According to the above evaluation method, sample acquisition is non-invasive and does not require the intervention of a professional. Compared to methods requiring blood sampling or biopsy, biomarker detection and results can be obtained more easily. For example, the subject himself can perform everything from sample acquisition to biomarker detection, and obtain an evaluation of the effectiveness of an antidepressant. Furthermore, by simply measuring and detecting biomarkers, objective and / or quantitative evaluation results can be obtained.

[0092] [Kit] The kit in one embodiment is a kit for evaluating the effect of an antidepressant in a subject, comprising a means for detecting any of the biomarkers described above in [Biomarkers] of this embodiment.

[0093] In one embodiment, the kit is a kit for carrying out the detection method described above in "Detection method" of this embodiment.

[0094] Examples and preferred examples of the "kit" are as described in [Kit] in the first embodiment.

[0095] The kit allows for non-invasive sample collection without the need for professional intervention, and allows for easier detection of biomarkers and results to be obtained compared to methods requiring blood sampling or biopsy. For example, the subject can perform the entire process from sample collection to biomarker detection and obtain an evaluation of the effectiveness of an antidepressant. Furthermore, by simply measuring and detecting biomarkers, objective and / or quantitative evaluation results can be obtained.

[0096] ==Fourth Embodiment (Marker for Determining Stress Level, Bacterial Species Composition)== [Biomarker] The biomarker according to the fourth embodiment is the composition of bacterial species in a bacterial population having sialic acid in a sample obtained from a subject. The biomarker of this embodiment can be used to determine the stress level experienced by the subject.

[0097] Sialic acid is a general term for 9-carbon sugar 2-keto-3-deoxynonanoic acids having a carboxyl group at carbon 1, and also for N- and / or O-acyl derivatives having neuraminic acid as a core structure. As used herein, sialic acid encompasses both narrow and broad definitions of sialic acid, including N-acetylneuraminic acid (Neu5Ac), N-glycolylneuraminic acid (Neu5Gc), deaminoneuraminic acid (Kdn), and the like. Sialic acid is not limited by its modification, and may be, for example, an O-acetylated form, an O-sulfated form, a lactone form, or a lactam form. In other words, the bacterial population containing sialic acid in this embodiment may be a bacterial population containing any of these sialic acids. A bacterial population containing sialic acid preferably comprises two or more bacteria having sialic acid attached to their cell surface sugar chains.

[0098] In a fourth embodiment, the composition of bacterial species of the phylum Firmicutes (p_Firmicutes) in a bacterial population in a sample obtained from a subject can also be used to determine the stress level to which the subject has been subjected. The bacterial population preferably includes two or more bacteria.

[0099] (Stress Level) The "stress level" in this embodiment is as described in the section "Stress Level" under [Biomarker] in the first embodiment.

[0100] (Sample) The sample is not limited to the type obtained from the subject, but is preferably a sample derived from the intestine of the subject. Using the composition of bacterial species in a bacterial population containing sialic acid contained in the intestine-derived sample, or the composition of bacterial species of the Firmicutes phylum (p_Firmicutes) in a bacterial population contained in the intestine-derived sample as a biomarker, makes it easier to determine the stress level of the subject with high accuracy and / or precision. Examples of intestine-derived samples include feces and intestinal mucosal tissue. Here, feces is not limited to biological samples derived from the intestine of the subject, and broadly encompasses intestinal contents. For example, it encompasses both intestinal contents after excretion from the subject's body (so-called feces) and intestinal contents before excretion. However, from the viewpoints of non-invasive sample acquisition and the absence of professional intervention, the intestine-derived sample is preferably feces excreted from the subject's body. The region of the intestine from which the intestinal contents are derived is not limited, and may be, for example, the small intestine including the duodenum, jejunum, and ileum, or the large intestine including the cecum, appendix, colon, and rectum. Here, the large intestine includes, for example, the ascending colon, transverse colon, descending colon, sigmoid colon, upper rectum, and lower rectum. When the sample is feces, it may be collected and stored according to techniques well known to those skilled in the art after excretion from the subject until the detection of the bacterial species composition, so as to prevent contamination with undesired substances not naturally contained in feces and / or to prevent changes in the bacterial species composition in the feces.

[0101] (Bacterial Species Composition) The bacterial species composition, which is a biomarker in this embodiment, is the composition of bacterial species in a bacterial population having sialic acid in a sample obtained from a subject, or the composition of bacterial species of the Firmicutes phylum (p_Firmicutes) in a bacterial population in a sample obtained from a subject. Considering the accuracy and / or precision of the determination, the bacteria are preferably intestinal bacteria that inhabit the intestine of the subject. Because intestinal samples may contain microorganisms other than bacteria, the "microbial population having sialic acid" may include microorganisms other than bacteria that have sialic acid. However, considering the accuracy and / or precision of the determination, it is preferable that the "microbial population having sialic acid" does not include microorganisms other than bacteria. The bacterial population having sialic acid may be all bacteria that have sialic acid among the bacteria contained in the sample, or may be a portion of the bacteria that have sialic acid. Here, the bacterial population having sialic acid is a bacterial population in which sialic acid is attached to the cell surface sugar chains. The cell surface sugar chain is not limited, and may be, for example, sialic acid-modified lipopolysaccharide, lipoteichoic acid, capsular polysaccharide, or the like.

[0102] A sample obtained from a subject usually contains multiple bacterial species; for example, it is said that there are more than 1,000 species of bacteria in the human intestine. The "composition of bacterial species in a bacterial population having sialic acid" refers to the content of any one or more bacterial species in the bacterial population having sialic acid. Here, "content" may be, for example, mass or bacterial cell number. Furthermore, "content" may be, for example, an absolute value or a relative value of the content of any one or more bacterial species in the bacterial population having sialic acid. In the case of an absolute value, it may be, for example, the mass of one or more bacterial species in a given mass of the bacterial population having sialic acid, or the bacterial cell number of one or more bacterial species in the bacterial population having sialic acid. In the case of a relative value, it may be, for example, the ratio of the mass or bacterial cell number of any one or more bacterial species to the mass or bacterial cell number of the bacterial population having sialic acid, or the ratio of the mass or bacterial cell number of any two or more bacterial species in the bacterial population having sialic acid. As used herein, the term "bacterial species" is not limited to the meaning of "species" of bacteria in biological classification, but refers to the type of bacteria in a broad sense. For example, if the composition of the detection target is a composition by bacterial class, order, or genus, it refers to the bacteria belonging to that classification. Furthermore, the "composition of bacterial species of the phylum Firmicutes in a bacterial population" refers to the content of one or more bacterial species belonging to the phylum Firmicutes (p_Firmicutes) in the bacterial population. Here, the "content" may be, for example, mass or bacterial cell count. Furthermore, the "content" may be, for example, an absolute value or a relative value of the content of any one or more bacterial species in the bacterial population. In the case of an absolute value, it may be, for example, the mass of one or more bacterial species belonging to the phylum Firmicutes (p_Firmicutes) in the bacterial population, or the bacterial cell count of one or more bacterial species belonging to the phylum Firmicutes in the bacterial population.In the case of a relative value, for example, it may be the ratio of the mass or number of bacterial cells of one or more bacterial species belonging to the phylum Firmicutes (p_Firmicutes) to the mass or number of bacterial cells of the bacterial population, or the ratio of the mass or number of bacterial cells of two or more bacterial species belonging to the phylum Firmicutes (p_Firmicutes) in the bacterial population. In this specification, "bacterial species" is not limited to the meaning of "species" of bacteria in biological classification, but refers to the type of bacteria in a broad sense; for example, if the composition to be detected is a composition by bacterial class, order, or genus, it refers to the bacteria belonging to that classification.

[0103] The bacterial species in the bacterial population having sialic acid are not limited to the extent that the composition of the bacterial species in the bacterial population having sialic acid correlates with the stress level of the subject, but may include the class Clostridia (c_Clostridia), order Clostridiales (o_Clostridiales), genus Ruminococcus (g_Ruminococcus), genus Lactobacillus (g_Lactobacillus), family Erysipelotrichaceae (f_Erysipelotrichaceae), Lactobacillus reuteri (g_Lactobacillus It is preferable that the bacterial strain contains any one or a combination of two or more bacterial species from the class Clostridia (c_Clostridia), the family Erysipelotrichaceae (f_Erysipelotrichaceae), the genus Lactobacillus (g_Lactobacillus), and the species Erysipelotrichaceae, and it is even more preferable that the bacterial strain contains bacteria from the class Clostridia (c_Clostridia). For example, when the bacterial species in a bacterial population having sialic acid are bacteria of the class Clostridia (c_Clostridia), the composition of the bacteria in the bacterial population having sialic acid can be used as a biomarker, whether it is a portion of the bacterial species of the class Clostridia (c_Clostridia) contained in the sample or all of the bacterial species of the class Clostridia (c_Clostridia) contained in the sample. For example, the composition of bacteria of the order Clostridiales (o_Clostridiales) and / or bacteria of other orders, or bacteria of the genus Clostridium (g_Clostridium) and / or bacteria of other genera, among the bacteria of the class Clostridia (c_Clostridia) in the bacterial population having sialic acid may be used as a biomarker.In one embodiment, the bacterial species composition in the bacterial population having sialic acid is preferably the content of bacteria of the class Clostridia (c_Clostridia) in the bacterial population having sialic acid.

[0104] The bacterial species of the phylum Firmicutes in the bacterial population are not limited as long as the composition of the bacterial species belonging to the phylum Firmicutes (p_Firmicutes) correlates with the stress level of the subject, but may be, for example, all bacterial species belonging to the phylum Firmicutes (p_Firmicutes) or bacterial species belonging to each class of the phylum Firmicutes. All bacterial species belonging to the phylum Firmicutes (p_Firmicutes) or bacterial species of the class Clostridia (c_Clostridia) are preferred.

[0105] Regarding the fecal microbiota, it is known that the relative amount of Clostridium (g_Clostridium) is similar between humans and mice (Thi Loan Anh Nguyen et al., How informative is the mouse for human gut microbiota research?, Disease Models & Mechanisms, Vol. 8 (1), Jan 2015, pages 1-16).

[0106] (Subject) Examples and preferred examples of the "subject" are as described in the "Subject" section of [Biomarker] in the first embodiment, except as follows.

[0107] In one embodiment, the biomarker for determining the stress level experienced by a subject according to this embodiment is preferably the composition of bacterial species in a bacterial population having sialic acid in a sample obtained from a human. In one embodiment, the biomarker for determining the stress level experienced by a subject according to this embodiment is more preferably the composition of bacterial species in a bacterial population having sialic acid in feces obtained from a human. In one embodiment, the biomarker for determining the stress level experienced by a subject according to this embodiment is even more preferably the content of bacteria of the class Clostridia (c_Clostridia) in feces obtained from a human.

[0108] In one embodiment, the biomarker for determining the stress level experienced by a subject according to this embodiment is preferably the composition of bacterial species belonging to the phylum Firmicutes (p_Firmicutes) in a bacterial population in a sample obtained from a human. In one embodiment, the biomarker for determining the stress level experienced by a subject according to this embodiment is more preferably the composition of bacterial species belonging to the phylum Firmicutes (p_Firmicutes) in a bacterial population in feces obtained from a human.

[0109] [Detection Method] In one embodiment, the detection method is a biomarker detection method for detecting any of the biomarkers described in the above [Biomarker] of this embodiment in a sample obtained from a subject. By the detection method described below, any of the biomarkers described in the above [Biomarker] of this embodiment can be detected in a sample obtained from a subject.

[0110] Here, examples and preferred examples of the "sample," "composition of bacterial species," and "subject" are as described above in [Biomarker] in this embodiment.

[0111] The sample is obtained from the subject as described in the "Detection method" of the first embodiment.

[0112] Pretreatment prior to biomarker detection can be performed on a sample obtained from a subject as described in the "Detection method" of the first embodiment, except for the following.

[0113] When the biomarker according to this embodiment is the composition of bacterial species in a bacterial population having sialic acid, the detection method according to this embodiment may include a step of isolating the bacterial population having sialic acid from a sample obtained from a subject. The bacterial population having sialic acid can be isolated from the sample using, for example, a lectin that specifically binds to sialylated sugar chains. The lectin to be used can be appropriately selected by those skilled in the art depending on the type of sialylated sugar chain to be bound. For example, Sambucus nigra lectin (Elderberry) bark (SNA), Limax flavus lectin (LFA), Triticum vulgaris lectin (WGA), Maackia amurensis lectin I (MAL I), Maackia amurensis lectin II (MAL II), Agrocybe cylindracea (ACG), Galectin 8 N-terminal domain (Gal8N), Sambucus sieboldiana lectin (SSA), Trichosanthes japonica lectin (TJAI), Polyporus squamosus lectin 1a (rPSL1a), Allomyrina dichtoma lectin (ADA), Escherichia coli lectin (SubB2M), Salmonella enterica lectin (PltB), Streptococcus gordonii lectin (HAS), Porcine Lectins such as hemagglutinating encephalomyelitis virus lectin (BCoV) can be used. Information on other lectins is available from the Lectin Frontier Database (LfDB) or from Odaka et al. (STAR ​​Protoc. 2022 Feb 18;3(1):101179. doi: 10.1016 / j.xpro.2022.101179.) and Minoshima et al. (iScience. 2021 Jul 17;24(8):102882. doi: 10.1016 / j.isci.2021.102882.).When the biomarker according to this embodiment is the composition of bacterial species in a bacterial population, the "bacterial population" does not need to include a step of isolating a bacterial population based on the presence or absence of sialic acid in a sample obtained from a subject. The composition of bacterial species in the entire bacterial population contained in the sample can be used as a biomarker.

[0114] The detection of a biomarker is not limited to the detection of the composition of bacterial species in a bacterial population having sialic acid, or the composition of bacterial species belonging to the phylum Firmicutes (p_Firmicutes) in the bacterial population. As described in the above [Biomarker] of this embodiment, the composition of bacterial species in a bacterial population having sialic acid may be the absolute value or relative value of the content of any one or more bacterial species in the bacterial population having sialic acid. Furthermore, the composition of bacterial species belonging to the phylum Firmicutes (p_Firmicutes) in the bacterial population may be the absolute value or relative value of the content of one or more bacterial species belonging to the phylum Firmicutes in the bacterial population. In this specification, the composition of a biomarker (the composition of bacterial species in a bacterial population, or the composition of a specific bacterial species in a bacterial population) is also referred to as the measurement value of the biomarker, and may be the presence or absence, absolute value, or relative value of the biomarker in a sample.

[0115] Here, the composition of bacterial species in a bacterial population having sialic acid, or the composition of bacterial species belonging to the phylum Firmicutes (p_Firmicutes) in a bacterial population, can be detected, for example, by a method comprising directly measuring the content of bacterial cells or measuring the amount of any substance derived from bacterial cells that correlates with the content of bacterial cells. When the amount of substance of bacterial cells is measured directly, for example, the mass of the bacterial population having sialic acid or the bacterial population itself and the mass of any one or more bacterial species contained in the bacterial population can be measured. When the number of bacterial cells is measured directly, for example, the number of bacterial cells constituting the bacterial population having sialic acid or the bacterial population itself and the number of bacterial cells of any one or more bacterial species contained in the bacterial population can be counted. These measurements make it possible to obtain absolute values ​​for the content of any one or more bacterial species in a bacterial population having sialic acid, or the composition of one or more bacterial species belonging to the phylum Firmicutes (p_Firmicutes) in a bacterial population. Furthermore, the composition of bacterial species can be detected by using the measurements obtained in these measurements to calculate, for example, the mass or ratio of the number of bacterial cells of any one or more bacterial species relative to the mass or number of bacterial cells of a bacterial population having sialic acid. Alternatively, the composition of bacterial species can be detected by calculating, for example, the mass or ratio of bacterial cells of any two or more bacterial species in a bacterial population having sialic acid. When measuring the amount of any substance derived from bacterial cells that correlates with the number of bacterial cells, for example, it is possible to measure the amount of any substance that correlates with the mass of a cell population having sialic acid or the number of bacterial cells constituting the bacterial population having sialic acid, and the amount of any substance that correlates with the mass or number of bacterial cells of any one or more bacterial species contained in the bacterial population. Using these measurements, the composition of bacterial species can be detected by calculating the ratio of any one or more bacterial species relative to the bacterial population having sialic acid, just as in the case of using absolute values. Alternatively, the composition of bacterial species can be detected by calculating the ratio of any two or more bacterial species in a bacterial population having sialic acid.Similarly, when the biomarker is the composition of bacterial species of the Firmicutes phylum (p_Firmicutes) in a bacterial population, the composition of bacterial species can be detected by calculating the mass or proportion of bacterial cells of one or more bacterial species belonging to the Firmicutes phylum (p_Firmicutes) in the bacterial population. Alternatively, for example, the composition of bacterial species can be detected by calculating the mass or proportion of bacterial cells of two or more bacterial species belonging to the Firmicutes phylum (p_Firmicutes) in the bacterial population.

[0116] For example, when the number of bacterial cells is measured directly, the number of bacterial cells may be counted under a microscope using a bacterial counting chamber, the number of colonies may be counted after inoculation onto an agar medium, the number of bacterial cells may be counted by inoculating onto a liquid medium and measuring the amount of transmitted light with a spectrophotometer and comparing it with a previously obtained standard, or the number of bacterial cells may be counted by measuring the weight of the bacteria and comparing it with a previously obtained standard.

[0117] For example, when measuring the amount of any substance correlated with the bacterial cell count, the amount of bacterial-derived ATP, the amount of bacterial-derived nucleic acid fragments, or the amount of sialic acid derived from a cell population bearing sialic acid may be measured, and the bacterial cell count may be counted by comparing these measured values ​​with a previously obtained standard. Alternatively, the Glycan sequence (Glycan-seq) method developed by Oinam et al. may be used to measure specific bacteria bearing sialic acid by binding lectins labeled with different DNAs to each sialylated sugar chain of the bacteria, and detecting the DNA using a method using primers and probes.

[0118] When measuring the amount of nucleic acid fragments derived from bacteria, a method can be used that uses different primers or probes for nucleic acid sequences that are specifically found in part or all of a specific bacterial population, such as the class Clostridia (c_Clostridia), order Clostridiales (o_Clostridiales), genus Ruminococcus (g_Ruminococcus), genus Lactobacillus (g_Lactobacillus), family Erysipelotrichaceae (f_Erysipelotrichaceae), Lactobacillus reuteri (g_Lactobacillus s_reuteri), order Lactobacillales (o_Lactobacillales), species Erysipelotrichaceae (s_Erysipelotrichaceae), or phylum Firmicutes (p_Firmicutes). The method can be appropriately selected by those skilled in the art, and examples thereof include specific quantitative PCR, T-RFLP (Terminal-Restriction Fragment Length Polymorphism), FISH (Fluorescence in situ hybridization), or a method using a microarray, a clone library method, DGGE / TGGE (Denaturing / Temperature Gradient Gel Electrophoresis), and metagenomic analysis.

[0119] More specifically, when using a method that uses different primers or probes for one or more bacterial species contained in a bacterial population that has sialic acid, or when using a method that uses different primers or probes for one or more bacterial species belonging to the phylum Firmicutes (p_Firmicutes) contained in a bacterial population, nucleic acids can be amplified by PCR using primers specific to each bacterial species, such as specific quantitative PCR or T-RFLP, and the amount of nucleic acid can be measured during or after the amplification reaction. Alternatively, nucleic acids can be detected using probes specific to bacterial genus without nucleic acid amplification, such as FISH or microarray methods. The primers and probes used may target corresponding regions on the nucleic acid of each bacterial species, or may target different regions. Specifically, for example, when using a 16S rRNA sequence, some or all of the nine variable regions can be targeted. More specifically, for example, the V3-V4 hypervariable region of the 16S rRNA gene may be targeted and this region specifically amplified by PCR.

[0120] A sequencer is typically used in methods using primers common to some or all of one or more bacterial species contained in a bacterial population with sialic acid, or in methods using primers common to some or all of one or more bacterial species belonging to the Firmicutes phylum (p_Firmicutes) contained in a bacterial population. The treatment of nucleic acids prior to sequencing can be appropriately selected by those skilled in the art. For example, in the clone library method, sequences specific to some or all of each bacterial species are amplified from extracted nucleic acids, and the amplified products are inserted into a plasmid for sequencing. In the DGGE / TGGE method, similarly amplified amplified products are separated by electrophoresis according to the nucleic acid strand sequence, extracted from the gel, and sequenced. In metagenomic analysis, nucleic acids are fragmented or amplified, and the products are directly sequenced. The primers used for amplification and sequencing may be the same or different. For example, when using 16S rRNA sequences, primers capable of hybridizing to conserved regions can be used. Such primers may include a forward primer having the nucleic acid sequence of SEQ ID NO: 83 and a reverse primer having the nucleic acid sequence of SEQ ID NO: 84. Sequencing can be performed using a sequencer that utilizes the principles of the Sanger method or a next-generation sequencer. Sequencing methods include, for example, multiplex methods, single-read methods, and paired-end methods, and can be selected appropriately by those skilled in the art.

[0121] The above-mentioned method for measuring the amount of any substance correlated with the bacterial cell count can also be performed using, for example, a commercially available kit. When measuring sialic acid derived from a cell population having sialic acid, the measurement can be appropriately performed according to a method well known to those skilled in the art. For example, the absolute amount can be determined by decomposing sialic acid-modified sugar chains into monosaccharides and quantifying the amount of sialic acid using liquid chromatography or mass spectrometry.

[0122] The method for identifying bacterial species from sequenced sequence information is not particularly limited. For example, analytical methods known in the art using analytical software, databases, etc. can be used. When using a database, for example, bacterial species can be identified by performing a sequence identity search on the accumulated bacterial base sequences. Specific examples of databases include GenBank, ENA, DDBJ, etc. In addition, the GREENGENES database, which is a database specialized in 16S rRNA sequences, can also be used. Alternatively, bacterial species may be identified by analysis using a microbial analysis tool such as the amplicon sequence data analysis software QIIME2 (Reproducible, interactive, scalable and extensible microbiome data science using QIIME 2. Bolyen E. et al., Nature Biotechnology 37: 852-857, 2019. doi.org / 10.1038 / s41587-019-0209-9).

[0123] According to the above detection method, sample acquisition is non-invasive, and by measuring and detecting biomarkers, objective and / or quantitative test results can be obtained.

[0124] [Method of Determination] The data collection method in one embodiment is a method of collecting data for determining the stress level experienced by a subject, including the detection method described in the above [Detection Method] of this embodiment.

[0125] In one embodiment, a stress level experienced by a subject can be determined based on the data collected by the data collection method, i.e., a method for determining a stress level experienced by a subject according to one embodiment includes the data collection method.

[0126] The composition of bacterial species in a bacterial population having sialic acid as a biomarker can be detected by any of the detection methods described above in [Detection Method] of this embodiment. The composition of bacterial species of the Firmicutes phylum (p_Firmicutes) in a bacterial population in a sample obtained from a subject as a biomarker can be detected by any of the detection methods described above in [Detection Method] of this embodiment.

[0127] In one embodiment, the data collection method for determining the stress level experienced by a subject may include, before performing any of the detection methods described in the above [Detection Method] of this embodiment on samples obtained from one or more individuals who have experienced a predetermined level of stress, performing the biomarker detection method according to the above [Detection Method] of this embodiment on samples obtained from the subject, to obtain reference values ​​of the biomarkers in the individuals who have experienced the predetermined level of stress. In another embodiment, the data collection method for determining the stress level experienced by a subject may include, before performing any of the detection methods described in the above [Detection Method] of this embodiment on samples obtained from the subject, performing the biomarker detection method according to the above [Detection Method] of this embodiment on samples obtained from one or more individuals who have experienced the predetermined level of stress and one or more individuals who have not experienced the predetermined level of stress, to obtain reference values ​​of the biomarkers in individuals who have experienced the predetermined level of stress and reference values ​​(normal values) of the biomarkers in individuals who have not experienced the predetermined level of stress. According to these methods, if the measured value of a biomarker in a sample obtained from a subject is the same as the reference value of the biomarker in an individual experiencing a predetermined level of stress, the subject may be determined to have experienced or be experiencing the predetermined level of stress, or to be likely to have experienced the predetermined level of stress, based on the data. Alternatively, if the measured value of a biomarker in a sample obtained from a subject is different from the reference value of the biomarker in an individual experiencing a predetermined level of stress, the subject may be determined to have not experienced or be likely to have experienced the predetermined level of stress, based on the data. Furthermore, if the measured value of a biomarker in a sample obtained from a subject is different from the normal value, the subject may be determined to have experienced or be experiencing the predetermined level of stress, or to be likely to have experienced the predetermined level of stress, based on the data.Alternatively, if the measured value of the biomarker in a sample obtained from a subject is the same as the normal value, it may be determined based on the data that the subject is not under a predetermined level of stress, or that there is a high possibility that the subject is not under a predetermined level of stress. In one embodiment, if the measured value of the biomarker in a sample obtained from a subject is elevated compared to the normal value, it may be determined based on the data that the subject has or has been under a predetermined level of stress, or that there is a high possibility that the subject has or has been under a predetermined level of stress. Since individuals under a predetermined stress tend to have a high or high content of bacteria of the class Clostridia (c_Clostridia) in a bacterial population having sialic acid in a sample compared to individuals not under stress, it may be determined that the subject has or is likely to be under a predetermined level of stress if the content of bacteria of the class Clostridia (c_Clostridia) in a sample obtained from the subject is high. Since the content of Clostridiales bacteria in a sialic acid-containing bacterial population in a sample from an individual subjected to a predetermined stress is high or tends to be high compared to a non-stressed individual, it may be determined that the subject has been subjected to a predetermined level of stress or is likely to be subjected to a predetermined level of stress when the content of Clostridiales bacteria in a sample obtained from the subject is high.Since the content of Ruminococcus bacteria in a sialic acid-containing bacterial population in a sample from an individual subjected to a predetermined stress is high or tends to be high compared to a non-stressed individual, it may be determined that the subject has been subjected to a predetermined level of stress or is likely to be subjected to a predetermined level of stress when the content of Ruminococcus bacteria in a sample obtained from the subject is high.Since the content of Erysipelotrichaceae bacteria in a sialic acid-containing bacterial population in a sample from an individual subjected to a predetermined stress is low or tends to be low compared to an individual not subjected to stress, it may be determined that the subject has experienced or is likely to have experienced a predetermined level of stress if the content of Erysipelotrichaceae bacteria in a sample obtained from the subject is low.Since the content of Lactobacillus bacteria in a sialic acid-containing bacterial population in a sample from an individual subjected to a predetermined stress is low or tends to be low compared to an individual not subjected to stress, it may be determined that the subject has experienced or is likely to have experienced a predetermined level of stress if the content of Lactobacillus bacteria in a sample obtained from the subject is low. In individuals subjected to a certain level of stress, the content of Lactobacillus reuteri (g_Lactobacillus s_reuteri) bacteria in the bacterial population containing sialic acid in a sample tends to be low compared to individuals not subjected to stress, so if the content of Lactobacillus reuteri (g_Lactobacillus s_reuteri) bacteria in a sample obtained from the subject is low, it may be determined that the subject has experienced or is likely to have experienced a certain level of stress.In individuals subjected to a certain level of stress, the content of Lactobacillales (o_Lactobacillales) bacteria in the bacterial population containing sialic acid in a sample tends to be low compared to individuals not subjected to stress, so it may be determined that the subject has experienced or is likely to have experienced a certain level of stress if the content of Lactobacillales (o_Lactobacillus) bacteria in a sample obtained from the subject is low.Since individuals subjected to a predetermined stress have a low or tend to have a low content of Erysipelotrichaceae bacteria in a bacterial population containing sialic acid in a sample compared to individuals not subjected to stress, it may be determined that the subject has experienced or is likely to have experienced a predetermined level of stress if the content of Erysipelotrichaceae bacteria in a sample obtained from the subject is low.Since individuals subjected to a predetermined stress have a high or tend to have a high content of Firmicutes bacteria in a bacterial population in a sample compared to individuals not subjected to stress, it may be determined that the subject has experienced or is likely to have experienced a predetermined level of stress if the content of Firmicutes bacteria in a sample obtained from the subject is high. Since individuals who have undergone a given level of stress have or tend to have a higher content of Clostridia bacteria in the bacterial population of a sample compared to individuals who have not undergone stress, if the content of Clostridia bacteria in a sample obtained from the subject is high, it may be determined that the subject has undergone or is likely to be undergoing a given level of stress.

[0128] In another embodiment, a method for collecting data to determine a stress level experienced by a subject may include, before performing any of the detection methods described in the above "Detection Method" of this embodiment on a sample obtained from the subject, performing the biomarker detection method according to the above "Detection Method" of this embodiment on samples obtained from multiple individuals or multiple groups of individuals each experiencing different levels of stress, and establishing a standard curve showing the relationship between stress level and biomarker level based on the biomarker levels in the individuals or groups of individuals experiencing different levels of stress. According to this method, if the measured value of the biomarker in the sample obtained from the subject is the same as any point on the standard curve, it may be determined based on the data that the subject has experienced or is experiencing a level of stress corresponding to that point, or that the subject is likely to have experienced or is likely to have experienced a predetermined level of stress. If the measured value of the biomarker in the sample obtained from the subject is different from any point on the standard curve, it may be determined based on the data that the subject has not experienced a level of stress corresponding to any point on the standard curve, or that the subject is likely to have experienced a level of stress corresponding to any point on the standard curve.

[0129] In another embodiment, a data collection method for determining a stress level experienced by a subject may include performing any of the detection methods described in the above "Detection Method" in this embodiment on multiple samples obtained over time from the same subject. According to this method, if the measured value of a biomarker in a sample obtained from the subject shows a change at a certain time point compared to a previous time point, the subject may be determined to have experienced or be experiencing a predetermined level of stress, or may be determined to have experienced or be likely to have experienced a predetermined level of stress, based on the data. For example, this method can be used to determine and monitor the stress level experienced or being experienced by a subject through periodic health checkups, etc. In one embodiment, if the measured value of a biomarker in a sample obtained from the subject shows an increase at a certain time point compared to a previous time point, the subject may be determined to have experienced or be experiencing a predetermined level of stress, or may be determined to have experienced or be likely to have experienced a predetermined level of stress, based on the data. For example, if the biomarker representing the composition of bacterial species in a bacterial population having sialic acid is the content of bacteria of the class Clostridia (c_Clostridia), the content of bacteria of the class Clostridia in the bacterial population having sialic acid in a sample will be higher or tend to be higher in stressed individuals or stressed individuals who have been administered an antidepressant compared to non-stressed individuals.

[0130] In one embodiment, any of the above determinations may be used to determine the level of stress experienced by the subject.

[0131] Here, the reference value, normal value, or standard curve may be the average or median value of biomarker measurements in samples obtained from individuals of the same group or from the same individual over time, or may be a reference range, normal range, or standard curve arbitrarily established based on biomarker measurements. Alternatively, the reference value, normal value, or standard curve may be a value that can determine the stress level of a subject with the desired accuracy and / or precision based on biomarker measurements in samples obtained from individuals of the same group or from the same individual over time, as appropriate determined by a person skilled in the art. Furthermore, a biomarker measurement value in a sample obtained from a subject being the same as a reference value, normal value, or any point on a standard curve means, for example, that there is no significant difference from the reference value or normal value using any statistical processing. A biomarker measurement value in a sample obtained from a subject that is different from a reference value, normal value, or point on a standard curve means, for example, that there is a significant difference from the reference value, normal value, or point on a standard curve using any statistical processing. The measurement value of a biomarker in a sample obtained from a subject being elevated compared to a reference value means, for example, that the measurement value of the biomarker in the sample obtained from the subject is significantly elevated compared to the reference value by any statistical processing. The statistical processing method can be appropriately selected by those skilled in the art according to well-known methods.

[0132] In one embodiment, the reference value may be 150%, 200%, 250%, 300%, 350%, 400%, 450%, or 500% or more of the normal value, and a value that allows a subject's stress level to be determined with the desired accuracy may be appropriately determined by a person skilled in the art.

[0133] In one embodiment, the above-described data collection method or the method for determining the stress level experienced by a subject based on the data collection method can also be implemented in combination with other data collection methods for determining the stress level experienced by a subject or other methods for determining the stress level experienced by a subject.

[0134] [Kit] In one embodiment, the kit is a kit for determining the stress level experienced by a subject, comprising means for detecting any of the biomarkers described above in [Biomarkers] of this embodiment.

[0135] In one embodiment, the kit is a kit for carrying out the detection method described above in "Detection method" of this embodiment.

[0136] In one embodiment, when the kit is a kit for carrying out a detection method for detecting the composition of bacterial species in a bacterial population having sialic acid, it includes, for example, a means for isolating a bacterial population having sialic acid in a sample obtained from a subject. Such a means includes, for example, a lectin that specifically binds to sialylated sugar chains. The lectin may be supported on any carrier suitable for isolating a cell population of interest. Examples of such lectins include Sambucus nigra Lectin (Elderberry) bark (SNA), Limax flavus lectin (LFA), Triticum vulgaris lectin (WGA), Maackia amurensis lectin I (MAL I), Maackia amurensis lectin II (MAL II), Agrocybe cylindracea (ACG), Galectin 8 N-terminal domain (Gal8N), Sambucus sieboldiana lectin (SSA), Trichosanthes japonica lectin (TJAI), Polyporus squamosus lectin 1a (rPSL1a), Allomyrina dichtoma lectin (ADA), Escherichia coli lectin (SubB2M), Salmonella enterica lectin (PltB), Streptococcus gordonii lectin (HAS), Porcine Hemagglutinating encephalomyelitis virus lectin (BCoV) and other lectins can be used. Information on other lectins can be found in the Lectin Frontier Database (LfDB), or in Odaka et al. (STAR ​​Protoc. 2022 Feb 18;3(1):101179. doi: 10.1016 / j.xpro.2022.101179.) and Minoshima et al. (iScience. 2021 Jul 17;24(8):102882. doi: 10.1016 / j.isci.2021.102882.).

[0137] In one embodiment, the kit includes means for directly measuring the cell count of bacterial cells, such as a counting chamber, an agar medium or one or more reagents for preparing an agar medium, and / or a liquid medium.

[0138] In one embodiment, the kit includes a means for measuring the amount of any substance correlated with bacterial cell count. For example, the means may be a means for measuring the amount of ATP, such as a fluorescent ATP sensor that can bind to ATP and detect its concentration. Alternatively, the kit may be a means for measuring the amount of bacterial-derived nucleic acid fragments, such as primers or probes for nucleic acid sequences specific to the bacterial population or species being detected. Other means include lectins, DNA labels, and primers or probes for detecting DNA, as used in the glycan sequencing (Glycan-seq) method developed by Oinam et al.

[0139] The kit may also include reagents for detecting the composition of the bacterial species, a positive control reagent to demonstrate that the detection process is working, and / or a storage solution for storing samples collected from the subject until the detection method is performed, and / or instructions on how to use the kit.

[0140] In one embodiment, the kit may include or be provided with the detection equipment necessary for detection.

[0141] In one embodiment, at least a part of the kit may be provided in a state of being attached to a part of a toilet bowl, which makes it easier to utilize the composition of bacterial species in a bacterial population having sialic acid in feces excreted by a subject for health management.

[0142] The kit allows for non-invasive sample collection, and by measuring and detecting biomarkers, objective and / or quantitative test results can be obtained.

[0143] Fifth Embodiment (Marker for Diagnosing Depression, Bacterial Species Composition) [Biomarker] A biomarker according to the fifth embodiment is a composition of bacterial species in a bacterial population having sialic acid in a sample obtained from a subject. The biomarker of this embodiment can be used to diagnose depression in a subject.

[0144] In a fifth embodiment, the composition of bacterial species of the phylum Firmicutes (p_Firmicutes) in a bacterial population in a sample obtained from a subject can also be used to diagnose depression in the subject.

[0145] It is known that stress is a trigger for depression, and therefore, the composition of bacterial species in a bacterial population having sialic acid or the composition of bacterial species of the phylum Firmicutes (p_Firmicutes) in a bacterial population in a sample obtained from a subject, which is a biomarker according to the fourth embodiment, can be used to diagnose depression in a subject.

[0146] Examples and suitable examples of "depression" are as described in the section "depression" under [biomarker] in the second embodiment.

[0147] (Sample) Examples and preferred examples of the "sample" are as described in the "Sample" section of [Biomarker] in the fourth embodiment.

[0148] (Composition of bacterial species) Examples and preferred examples of the "composition of bacterial species" are as described in the section "Composition of bacterial species" in [Biomarker] of the fourth embodiment.

[0149] (Subject) Examples and preferred examples of the "subject" are as described in the "Subject" section of [Biomarker] in the fourth embodiment.

[0150] [Detection Method] The detection method in one embodiment is a biomarker detection method in which any of the biomarkers described above in [Biomarker] of this embodiment is detected in a sample obtained from a subject.

[0151] Here, examples and preferred examples of the "sample," "composition of bacterial species," and "subject" are as described above in [Biomarker] in this embodiment.

[0152] In this embodiment, the acquisition of a sample from a subject, the pretreatment prior to the detection of a biomarker, and the detection of a biomarker are as described in the "Detection method" of the fourth embodiment.

[0153] According to the above detection method, sample acquisition is non-invasive, and by measuring and detecting biomarkers, objective and / or quantitative test results can be obtained.

[0154] [Diagnostic Method] The data collection method in one embodiment is a data collection method for diagnosing depression in a subject, which includes the detection method described in the above [Detection Method] of this embodiment.

[0155] In one embodiment, the presence of depression in a subject can be diagnosed based on the data collected by the data collection method. That is, a method for diagnosing depression in a subject according to one embodiment includes the data collection method.

[0156] The composition of bacterial species in a bacterial population having sialic acid as a biomarker can be detected by any of the detection methods described above in [Detection Method] of this embodiment. The composition of bacterial species of the Firmicutes phylum (p_Firmicutes) in a bacterial population in a sample obtained from a subject as a biomarker can be detected by any of the detection methods described above in [Detection Method] of this embodiment.

[0157] In one embodiment, the method for collecting data for diagnosing depression in a subject may comprise, before performing any of the detection methods described in the above [Detection Method] of this embodiment on a sample obtained from the subject, performing the biomarker detection method according to the above [Detection Method] of this embodiment on samples obtained from one or more depressed patients to obtain reference values ​​of the biomarkers in depressed patients. In another embodiment, the method for collecting data for diagnosing depression in a subject may comprise, before performing any of the detection methods described in the above [Detection Method] of this embodiment on samples obtained from the subject, performing the biomarker detection method according to the above [Detection Method] of this embodiment on samples obtained from one or more depressed patients and one or more healthy subjects to obtain reference values ​​of the biomarkers in depressed patients and reference values ​​(normal values) of the biomarkers in healthy subjects. According to these methods, if the measured value of a biomarker in a sample obtained from a subject is the same as the reference value of the biomarker in depressed patients, the subject may be determined to have depression or to have a high probability of having depression based on the data. Alternatively, if the measured value of a biomarker in a sample obtained from a subject is different from the reference value of the biomarker in depressed patients, the subject may be determined to not have depression or to have a high probability of not having depression based on the data. Furthermore, if the measured value of a biomarker in a sample obtained from a subject is different from the normal value, the subject may be determined to have depression or to have a high probability of not having depression based on the data. Alternatively, if the measured value of a biomarker in a sample obtained from a subject is the same as the normal value, the subject may be determined to not have depression or to have a high probability of not having depression based on the data.In one embodiment, when the measured value of a biomarker in a sample obtained from a subject is elevated compared to a normal value, the subject may be determined to be suffering from depression or to be highly likely to be suffering from depression based on the data. Since depressed patients or depressed patients administered antidepressants tend to have a higher or higher content of Clostridia bacteria in a bacterial population having sialic acid in a sample compared to healthy subjects, when the content of Clostridia bacteria in a sample obtained from a subject is high, the subject may be determined to be suffering from (or have been suffering from) depression, or to be highly likely to have been suffering from (or have been suffering from) depression. In depressed patients or depressed patients administered antidepressants, the content of Clostridiales bacteria in a bacterial population containing sialic acid in a sample is higher or tends to be higher than in healthy subjects. Therefore, if the content of Clostridiales bacteria in a sample obtained from a subject is high, it may be determined that the subject is suffering from (or has suffered from) depression, or that there is a high possibility that the subject has suffered from (or has suffered from) depression. In depressed patients or depressed patients administered antidepressants, the content of Ruminococcus bacteria in a bacterial population containing sialic acid in a sample is higher or tends to be higher than in healthy subjects. Therefore, if the content of Ruminococcus bacteria in a sample obtained from a subject is high, it may be determined that the subject is suffering from (or has suffered from) depression, or that there is a high possibility that the subject has suffered from (or has suffered from) depression. In depressed patients or depressed patients administered antidepressants, the content of Erysipelotrichaceae bacteria in the bacterial population containing sialic acid in a sample is low or tends to be low compared to healthy individuals. Therefore, if the content of Erysipelotrichaceae bacteria in a sample obtained from a subject is low, it may be determined that the subject is (has) suffering from depression, or that there is a high possibility that the subject is (has) suffering from depression.In depressed patients or depressed patients administered with antidepressants, the content of Lactobacillus (g_Lactobacillus) bacteria in the bacterial population with sialic acid in the sample is low or tends to be low compared to healthy individuals. Therefore, if the content of Lactobacillus (g_Lactobacillus) bacteria in the sample obtained from the subject is low, it can be determined that the subject is suffering from (having suffered from) depression, or that there is a high possibility that the subject is suffering from (having suffered from) depression. In depressed patients or depressed patients administered with antidepressants, the content of Lactobacillus reuteri (g_Lactobacillus s_reuteri) bacteria in the bacterial population with sialic acid in the sample is low or tends to be low compared to healthy individuals. Therefore, if the content of Lactobacillus reuteri (g_Lactobacillus s_reuteri) bacteria in the sample obtained from the subject is low, it can be determined that the subject is suffering from (having suffered from) depression, or that there is a high possibility that the subject is suffering from (having suffered from) depression. In depressed patients or depressed patients administered antidepressants, the content of Lactobacillales bacteria in the bacterial population containing sialic acid in the sample is low or tends to be low compared to healthy subjects, so if the content of Lactobacillales bacteria in the sample obtained from the subject is low, it can be determined that the subject is suffering from (or has suffered from) depression, or that there is a high possibility that the subject has suffered from (or has suffered from) depression.In depressed patients or depressed patients administered antidepressants, the content of Erysipelotrichaceae bacteria in the bacterial population containing sialic acid in the sample is low or tends to be low compared to healthy subjects, so if the content of Erysipelotrichaceae bacteria in the sample obtained from the subject is low, it can be determined that the subject is suffering from (or has suffered from) depression, or that there is a high possibility that the subject has suffered from (or has suffered from) depression.In depressed patients or depressed patients administered antidepressants, the content of bacteria of the phylum Firmicutes (p_Firmicutes) in the bacterial population of a sample is higher or tends to be higher compared to healthy subjects, so if the content of bacteria of the phylum Firmicutes (p_Firmicutes) in a sample obtained from a subject is high, it may be determined that the subject is (has) suffering from depression, or that there is a high possibility that the subject has (had) suffered from depression. In depressed patients or depressed patients administered antidepressants, the content of bacteria of the class Clostridia (c_Clostridia) in the bacterial population of a sample is higher or tends to be higher compared to healthy subjects, so if the content of bacteria of the class Clostridia (c_Clostridia) in a sample obtained from a subject is high, it may be determined that the subject is (has) suffering from depression, or that there is a high possibility that the subject has (had) suffered from depression.

[0158] In another embodiment, a method for collecting data for diagnosing depression in a subject may include performing any of the detection methods described in the above "Detection Method" in this embodiment on multiple samples obtained over time from the same subject. According to this method, if the measured value of a biomarker in a sample obtained from the subject shows a change at a certain time point compared to previous values, the subject may be determined to have depression or to have a high probability of having depression based on the data. For example, this method can be used to monitor the subject's depression through periodic health checkups, etc. In one embodiment, if the measured value of a biomarker in a sample obtained from the subject shows an increase at a certain time point compared to previous values, the subject may be determined to have depression or to have a high probability of having depression based on the data. For example, when the biomarker representing the composition of bacterial species in a bacterial population having sialic acid is the content of bacteria of the class Clostridia (c_Clostridia), the content of bacteria of the class Clostridia in the bacterial population having sialic acid in the sample from patients with depression is higher or tends to be higher than that from healthy individuals.

[0159] In one embodiment, the subject can be diagnosed with depression by any of the above determinations.

[0160] Here, the reference value or normal value may be the average or median value of the biomarker measurements in samples obtained from the same group of subjects or from the same subject over time, or may be a reference range or normal range arbitrarily established based on the biomarker measurements. Alternatively, the reference value or normal value may be a value that can determine the presence of depression in a subject with the desired accuracy based on the biomarkers in samples obtained from the same group of subjects or from the same subject over time, as appropriate, determined by a person skilled in the art. Furthermore, the measurement value of a biomarker in a sample obtained from a subject being the same as the reference value or normal value means, for example, that there is no significant difference from the reference value or normal value as determined by any statistical processing. The measurement value of a biomarker in a sample obtained from a subject being different from the reference value or normal value means, for example, that there is a significant difference from the reference value or normal value as determined by any statistical processing. The measurement value of a biomarker in a sample obtained from a subject being elevated compared to the reference value means, for example, that the measurement value of a biomarker in a sample obtained from a subject is significantly elevated compared to the reference value as determined by any statistical processing. The statistical processing method can be appropriately selected by a person skilled in the art according to well-known methods.

[0161] In one embodiment, the reference value may be 150%, 200%, 250%, 300%, 350%, 400%, 450%, or 500% or more of the normal value, and a value that allows a subject to be determined to have depression with a desired accuracy and / or precision may be appropriately determined by a person skilled in the art.

[0162] In one embodiment, the above-described data collection method or the method for diagnosing the onset of depression based on the data collection method can also be performed in combination with other data collection methods for diagnosing depression or other methods for diagnosing depression.

[0163] [Kit] The kit in one embodiment is a kit for diagnosing depression in a subject, comprising means for detecting any of the biomarkers described above in [Biomarkers] of this embodiment.

[0164] In one embodiment, the kit is a kit for carrying out the detection method described above in "Detection method" of this embodiment.

[0165] Examples and preferred examples of the "kit" are as described in the "kit" of the fourth embodiment.

[0166] The kit allows for non-invasive sample collection, and by measuring and detecting biomarkers, objective and / or quantitative test results can be obtained.

[0167] The present invention will be explained in more detail below by showing examples, but the interpretation of the present invention is not limited to these examples.

[0168] [Example 1] Model Animals The model animals used in the following examples are as follows. (1) Chronic Mild Stress Model Mouse Group Stress-vulnerable mice (BALB / c mice) were subjected to chronic mild stress (the following stress loads were randomly administered for 24 hours: exposure to acetic acid odor, swapping the cage with another mouse's cage, wetting the bedding, living in a cramped and narrow environment, tilting the cage, crushing food to make it difficult to eat, and reversing light and dark) for 6 weeks. The mice subjected to chronic mild stress were designated as the chronic ultra-mild stress (CUMS) group. (2) Control Group Stress-vulnerable mice (BALB / c mice) not subjected to the chronic mild stress described in (1) above were designated as the control group. (3) Antidepressant-treated group The chronic mild stress model mice described in (1) above were treated with imipramine hydrochloride (Sigma-Aldrich) (dissolved in drinking water in an amount equivalent to 18 mg / kg / day and taken orally for 3 weeks) and designated as the antidepressant-treated (CUMS + antidepressant, IMI + CUMS) group.

[0169] Example 2: Analysis of bacterial composition in fecal samples. Mice (n = 6) from the CUMS group, control group, and CUMS + antidepressant group were placed in sterilized cages for 30 to 60 minutes, and excreted feces were collected with sterilized tweezers. The feces were stored at -20°C until analysis. Bacteria were isolated from the feces by density gradient centrifugation. Specifically, approximately 20 mg of feces was placed in 0.5 mL of phosphate-buffered saline (PBS) and homogenized overnight at 750 rpm at 4°C. The supernatant of the suspension was collected and transferred to an 80% w / v Nycodenz aqueous solution (Serumwerk Bernburg) and centrifuged at 10,000 × g for 40 minutes at 4°C. The bacterial interphase was collected and washed with PBS. Bacterial cells were eluted with 0.2 M lactose.

[0170] Sequencing libraries were prepared according to the Illumina "16S Metagenomic Sequencing Library Preparation" protocol, targeting the V3-V4 hypervariable region of the 16S rRNA gene. The V3-V4 region was amplified by PCR using KAPA HiFi HotStart ReadyMix (Roche) containing 1 μl of extracted fecal microbial DNA and 1 μM of each of the following primers: Forward: 5'-TCGTCGCAGCGTCAGATGTGTATAAGACAGCCTACGGNGGCWGCAG-3' (SEQ ID NO: 83) Reverse: 5'-GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGGACTACHVGGGTATCTAATCC-3' (SEQ ID NO: 84). The PCR product was purified using Agentcourt AMPure XP magnetic beads (Beckman Coulter). A second PCR was performed using 2.5 μl of the purified product and Illumina index primers under the following reaction cycle: initial denaturation at 95°C for 3 minutes; 8 cycles of denaturation at 95°C for 30 seconds, annealing at 55°C for 30 seconds, and extension at 72°C for 5 minutes; final extension at 72°C for 5 minutes. The final product was again purified using Agent AMPure XP and eluted with 10 mM Tris pH 8.5 (elution buffer). The purified amplicons were quantified using MultiNA (Shimadzu). The amplicons were then sequenced on the Illumina MiSeq 2 × 250 bp platform using the MiSeq Reagent Nano Kit V2 (Illumina).

[0171] Raw sequencing reads were preprocessed using the amplicon sequencing data analysis software QIIME2 (ver. 2020 / 8, https: / / qiime2.org / , Reproducible, interactive, scalable, and extensible microbiome data science using QIIME 2. Bolyen E. et al., Nature Biotechnology 37: 852-857, 2019. doi.org / 10.1038 / s41587-019-0209-9). The DADA2 plugin was used to demultiplex reads, perform denoise quality control, trim reads, and assemble sequences. Amplicon sequence variants (ASVs) generated by the DADA2 algorithm were classified using the q2-feature-classifier. The output artifacts were compiled into a phyloseq object in R version 4.1.2 (2021-11-01), diluted at equal depths for each sample, and β-diversity was calculated based on the Bray-Curti dissimilarity metric using principal coordinate analysis (PCoA).

[0172] The results of the analysis (principal coordinate analysis) are shown in Figure 1. The plots representing individual mice were closely spaced among the CUMS group, the control group, and the CUMS + antidepressant group, and no significant differences were observed among the groups in the bacterial flora (bacterial composition) obtained from the fecal samples.

[0173] After PCR, the sequence data was sequenced on the Illumina MiSeq 2x250 bp platform using the MiSeq Reagent Nano Kit V2 (Illumina) and analyzed using Linear Discriminant Analysis EfSe (LEfSe) (Segata et al., Metagenomic biomarker discovery and explanation, Genomic Biol. 2011; 12(6): R60, doi. 10.1186 / gb-2011-12-6-r60). The results showed that the number of bacteria belonging to the phylum Firmicutes (p_Firmicutes, including the class Clostridia (c_Clostridia)) was significantly higher in the CUMS group (Figure 2).

[0174] The composition of bacterial species in the bacterial population in a fecal sample can be used as a biomarker for determining the stress level experienced by a subject and / or as a biomarker for diagnosing depression in a subject.

[0175] Example 3: Analysis of Sialylated Sugar Chains of Fecal-Derived Bacteria Using Glycan-seq Method The following analysis was performed using the Glycan-seq method developed by Oinam et al. Mice (n = 6) from the CUMS group, control group, and CUMS + antidepressant-treated group were placed in sterilized cages for 30 to 60 minutes, and excreted feces were collected with sterilized tweezers. The feces were stored at -20°C until analysis. Bacteria were isolated from the feces by density gradient centrifugation. Specifically, approximately 20 mg of feces was placed in 0.5 mL of phosphate-buffered saline (PBS) and homogenized by shaking overnight at 750 rpm at 4°C. The supernatant was collected and transferred to an 80% w / v Nycodenz aqueous solution (Serumwerk Bernburg) and centrifuged at 10,000 × g for 40 minutes at 4°C. The interlayer containing the bacteria was collected and washed with PBS. The number and size of bacterial cells were measured using a particle counter analyzer (CDA-1000, Sysmex).

[0176] (Preparation of DNA-barcoded lectins) 100 μg of each lectin (see "Name" in Table 1) was dissolved in 100 μl of PBS mixed with a 10-fold molar ratio of dibenzocyclooctyne-N-hydroxysuccinimidyl ester (DBCO-NHS, Funakoshi) and incubated at 20°C for 1 hour in the dark. 10 μl of 1 M Tris was added to inactivate the DBCO-NHS, and the mixture was incubated at 20°C for 15 minutes in the dark. Excess DBCO-NHS was removed using Sephadex G-25 desalting columns (GE Healthcare Japan). Each DBCO-labeled lectin (100 μg / mL) was mixed with a 5'-azido-modified DNA oligonucleotide (Integrated DNA Technologies, 10-fold molar amount, SEQ ID NOS: 1 to 41) having a sequence corresponding to the lectin shown in the "Name" column in Table 1. Furthermore, using Sepharose 4B-CL (GE Healthcare Japan), to which sugars with affinity based on the sugar-binding specificity of each lectin were immobilized, the lectin with each sugar-binding affinity was purified by affinity chromatography, and excess nucleotides were removed to prepare a lectin-DNA oligonucleotide conjugate.

[0177] (Glycan-seq method) Bacterial cells (1 x 10 7) were suspended in PBS containing 1% bovine serum albumin (BSA) (PBS / BSA) and incubated with 39 lectins barcoded with DNA (SEQ ID NOS: 1 to 41) and two negative control proteins (final concentration: 0.5 μg / mL) at 4°C for 1 hour. The bacterial cells were washed three times with PBS / BSA and irradiated with UV light at 365 nm, 15 W, for 15 minutes using a long-wavelength black light UV bench lamp (UVP Blak-Ray XX-15L UV Bench Lamp, Analytik Jena). The released oligonucleotides were amplified by PCR using NEBNext Ultra II Q5 Master Mix (New England BioLabs) and i5-index primers (Integrated DNA Technologies, Table 2 (SEQ ID NOs: 85, 87-104) containing the oligonucleotide sequences) and i7-index primers (Integrated DNA Technologies, Table 2 (SEQ ID NOs: 86, 105-122)). PCR consisted of one cycle of denaturation (98°C, 45 seconds), 20 cycles of denaturation (98°C, 10 seconds, followed by 65°C, 50 seconds), and one cycle of extension (65°C, 5 minutes). This PCR allowed the detection of DNA barcodes corresponding to the various lectins listed in Table 1. Furthermore, by using primer pairs with different adapters ("Bases in Adapter" in Table 2), experimental groups could be distinguished and detected even in mixed PCR products. PCR products were amplified using Agencourt AMPure XP PCR kit. The PCR products were purified using a PCR Reagent Kit (Beckman Coulter). The size and quality of the PCR products were analyzed using a MultiNA (Shimadzu). The PCR products (4 nM) from each sample were processed using the MiSeq Reagent Kit v2 (Illumina) and sequenced using a MiSeq Sequencer (Illumina).

[0178] The information of the DNA barcodes released from the lectins was directly extracted in FASTQ format.

[0179] DNA barcode sequences corresponding to each lectin were extracted from the FASTQ-formatted file, and the number of DNA barcodes was counted using the barcode DNA counting system (Mizuho Research & Technologies). The DNA barcode sequences unique to each lectin used to count the number of DNA barcodes are shown in Table 1 under "Lectin barcode sequence for NGS" (SEQ ID NOs: 42-82). The total number of DNA barcodes was divided by the total number of lectin barcodes, and the percentage (%) of each lectin was expressed. The statistical significance level of lectins in Glycan-seq was evaluated by abundance analysis of compositional data adapted from Analysis of Compositions of Microbiomes (ANCOM) with Holm-Bonferroni multiple hypothesis correction, and statistically significant lectins with p<0.05 were selected.

[0180] The results showed that the amount of DNA barcode corresponding to Sambucus nigra Lectin (Elderberry) bark (SNA), a sialic acid-binding lectin, was significantly lower in the CUMS group compared to the control group and the CUMS + antidepressant group. Meanwhile, there was no significant difference between the CUMS + antidepressant group and the control group (Figure 3, *: p<0.05). These results indicate that the CUMS group had significantly lower binding of SNA to bacterial cells in the sample compared to the control group, while the CUMS + antidepressant group had recovered to the same level of binding of SNA to bacterial cells in the sample as the control group.

[0181] Example 4: Sociability Test A field (30 cm long, 30 cm wide, 16 cm high) was prepared with a cage (cylindrical, 10 cm diameter, 17.5 cm high, 23 grids, 8 mm grid spacing) at one end, and one target mouse was placed in the cage. Mice (n=6) from each experimental group were placed in the field one by one, and their behavior was observed for 3 minutes. During the observation period, the shorter the time that the experimental group mice spent in the target area (12 cm long x 20 cm wide, centered on the target mouse), the less interest they had, which is considered to be behavior reflecting stress load on the individual or depressive-like behavior.

[0182] In the CUMS group, the approach time (seconds) to the target mouse in the sociability test was significantly shorter, i.e., behavior reflecting stress load or depressive-like behavior was strongly observed. On the other hand, the control group and the CUMS + antidepressant group had significantly longer approach times to the target mouse in the sociability test. These results are shown in Figure 4 (*: p<0.05).

[0183] (Lectin Binding and Sociability Test) The results of an analysis of the correlation between the binding of SNA in Example 3 and the results of the sociability test in this example are shown in Figure 5. In the CUMS group, which had low lectin binding, the approach time to the target mouse in the sociability test was short, i.e., behavior reflecting stress load or depressive-like behavior was strongly observed. On the other hand, in the control group and the CUMS + antidepressant group (IMI + CUMS), which had high lectin binding, the approach time to the target mouse in the sociability test was long. Therefore, a significant correlation was observed between SNA binding and the target approach time in the sociability test (R = 0.67, p = 0.0026).

[0184] Example 5 Analysis of bacterial species composition in a bacterial population containing sialic acid 1 μg / μl of SNA was labeled with biotin and incubated with streptavidin-conjugated Dynabeads (Thermo Fisher Scientific) for 1 hour on a shaker set at 1,400 rpm and 4°C. 1 × 10 SNA was isolated from feces from three sample groups (control group, CUMS group, CUMS + antidepressant administration group) (n = 6) in the same manner as in Example 3. 7 Bacterial cells were incubated with the washed SNA-bound beads overnight on a shaker at 700 rpm and 4°C. The bound bacterial cells were separated using magnetic beads and eluted with 0.2 M lactose. As described in Example 2, a sequencing library was prepared targeting the V3-V4 hypervariable region of the 16S rRNA gene, and the V3-V4 region was amplified by PCR. The PCR product was purified, a second PCR was performed, and the purified product was sequenced, as described in Example 2.

[0185] Furthermore, as described in Example 2, α-diversity (Wilcoxon pairwise test, p<0.05) and β-diversity based on the Bray-Curti dissimilarity metric were calculated by principal coordinate analysis (PCoA).

[0186] The results of the analysis are shown in Figure 6. As shown in Figure 6, the number of sialic acid-added Clostridia (c_Clostridia) bacteria cells was significantly higher in the CUMS group and the CUMS + antidepressant-administered group (IMI + CUMS) compared to the control group. In addition, the number of sialic acid-added Clostridiales (o_Clostridiales) bacteria and Ruminococcus (g_Ruminococcus) bacteria cells was significantly higher in the CUMS group and the CUMS + antidepressant-administered group compared to the control group. On the other hand, compared to the CUMS group or the CUMS + antidepressant group, the control group had significantly higher cell counts of sialic acid-added Lactobacillus genus (g_Lactobacillus), Erysipelotrichaceae family bacteria (f_Erysipelotrichaceae), Lactobacillus reuteri (g_Lactobacillus s_reuteri), Lactobacillales order bacteria (o_Lactobacillales), and Erysipelotrichaceae bacteria.

[0187] (Open field test) Mice from each group were placed in an open field measuring 30 cm in length, 30 cm in width, and 16 cm in height, and the time spent in the central 10 cm square field was measured. This time is an index of anxious behavior, and it is known that the stronger the anxiety, the shorter the time spent in the center.

[0188] Figure 7 shows the relationship between the time (seconds, vertical axis) that mice spent in the center of the open field test (OFT) and the number of sialylated Lactobacillus reuteri (g_Lactobacillus s_reuteri) and sialylated Clostridiales (o_Clostridiales) bacteria cells. The longer the time that mice spent in the center of the open field test, the greater the number of sialylated Lactobacillus reuteri (g_Lactobacillus s_reuteri) bacteria cells, with a significant correlation (R = 0.7, p = 0.0014) (Figure 7, left). The shorter the time that mice spent in the center of the open field test, the greater the number of sialylated Clostridiales bacteria cells, with a significant correlation (R = -0.55, p = 0.017) (Figure 7, right).

[0189] These results indicate that the cell counts of sialic acid-containing bacteria belonging to the class Clostridia (c_Clostridia), order Clostridiales (o_Clostridiales), genus g_Ruminococcus, genus g_Lactobacillus, family Erysipelotrichaceae (f_Erysipelotrichaceae), Lactobacillus reuteri (g_Lactobacillus s_reuteri), order o_Lactobacillales, and species Erysipelotrichaceae (s_Erysipelotrichaceae) are significantly different between the control group and the CUMS and CUMS plus antidepressant groups. These bacterial cell counts can be used to assess stress levels and / or as biomarkers for diagnosing depression. Furthermore, the composition of bacterial species in a population of sialic acid-containing bacteria can be used as a biomarker for assessing the stress level of a subject and / or for diagnosing depression in a subject.

[0190] Example 6 Analysis of Sialidase Activity Ten mg of feces was added to 1 ml of Tris-HCl buffer (0.15 M NaCl, 1% PBSTx (0.25% Triton-X 100 (PBS + Tx), pH 6.7) and homogenized on ice using a biomasher (Nippi, product code: 320103). The homogenized feces was incubated on ice for 1 hour and then centrifuged at 4,000 g for 3 minutes. The supernatant was collected and passed through a Durapore membrane filter (MilliporeSigma, catalog number: UFC30GV0S), followed by centrifugation at 15,000 rpm for 10 minutes. The separated protein was quantified using the Pierce® BCA Protein Assay Kit (Thermo Fisher Scientific, catalog number: 23225). Samples containing 10 μg of protein were subjected to Neuraminidase assay. Sialidase activity was measured using a kit (Sigma-Aldrich, MAK121) according to the protocol. Eighty μl of the reaction mixture and 20 μl of each sample and standard were added to each well of a 96-well plate (Proteosave SS 96F plate, SUMILON, catalog number: MS-8296F) and incubated at 37°C for 80 minutes in the dark. After 80 minutes, absorbance was measured at 570 nm (colorimetric measurement) using a SpectraMax multimode microplate reader (Molecular Devices Japan).

[0191] The results of the analysis are shown in Figure 8. Sialidase activity was significantly higher in the CUMS group compared to the control group or the CUMS + antidepressant administration group (IMI + CUMS) (p<0.05).

[0192] (Forced Swimming Test (FST)) A cylindrical container 20 cm high and 14 cm in diameter was filled with water at 23±0.5°C to a depth of 13 cm, and mice were made to swim in it. They were observed for 5 minutes to measure the immobility time. The immobility time is an index of stress load and depressive-like behavior in an individual, and it is thought that the shorter the immobility time, the stronger the anti-stress and antidepressant effects.

[0193] The relationship between immobility time (seconds, horizontal axis) in the forced swimming test and sialidase activity (vertical axis) in mouse fecal samples is shown in Figure 9. The longer the immobility time in the forced swimming test, the higher the sialidase activity, and a significant correlation was observed (R = 0.85, p = 0.0034).

[0194] (Clostridium (c_Clostridia) Bacterial Cell Count and Sialidase Activity) The results of analyzing the correlation between the Clostridium (Clostridia) bacterial cell count in Example 2 and the sialidase activity in this example are shown in Figure 10. A significant correlation was observed between the Clostridia (c_Clostridia) bacterial cell count and sialidase activity (R = 0.88, p = 0.004).

[0195] (Cell count and sialidase activity of bacteria belonging to the phylum Firmicutes (p_Firmicutes), including the class Clostridia (c_Clostridia)) in Example 2. The results of an analysis of the correlation between the cell count of bacteria belonging to the phylum Firmicutes (p_Firmicutes), including the class Clostridia (c_Clostridia), and the sialidase activity in this example are shown in Figure 11. A significant correlation was observed between the cell count of bacteria belonging to the phylum Firmicutes (p_Firmicutes) and sialidase activity (R = 0.83, p = 0.011).

[0196] Example 7 Analysis of Human Clinical Samples Fecal samples from one healthy human subject (Lot No. 22-08-527) and one depressed patient (Lot No. 22-08-535) were purchased from Medix Biochemica. The conditions for the healthy subject and the depressed patient are shown in Table 3. Sialidase activity was measured in the same manner as in Example 6 using mouse feces, except that the test sample for sialidase activity measurement contained 100 μg of protein instead of 10 μg.

[0197] The analysis results are shown in Figure 12 and Table 3. In healthy individuals (control group), the absorbance (OD) indicating sialidase activity was 0.4685, while in depressed patients, the absorbance (OD) indicating sialidase activity was 1.072. This indicates that sialidase activity in fecal samples is higher in depressed patients than in healthy individuals.

[0198] These results suggest that bacterial sialidase activity in fecal samples can be used as a biomarker for determining the stress level of a subject and / or for diagnosing depression in a subject. Furthermore, since the sialidase activity in individuals treated with antidepressants is comparable to that in healthy individuals, sialidase activity can be used as a biomarker for evaluating the efficacy of antidepressants.

[0199] Sialidase activity in a sample obtained from a subject reflects the stress level experienced by the subject, whether the subject suffers from depression, and the effectiveness of antidepressants in the subject. Furthermore, the composition of bacterial species in a bacterial population having sialic acid in a sample obtained from a subject reflects the stress level experienced by the subject and whether the subject suffers from depression. Therefore, sialidase activity in a sample obtained from a subject and the composition of bacterial species in a bacterial population having sialic acid are suitable as markers for evaluating the stress level experienced by the subject, whether the subject suffers from depression, and / or the effectiveness of antidepressants in the subject, and have industrial applicability.

Claims

1. A biomarker for determining the stress level experienced by a subject, the biomarker being sialidase activity derived from bacteria in a sample obtained from the subject.

2. The biomarker of claim 1, wherein the sample is feces.

3. The biomarker of claim 1, wherein the bacteria comprises bacteria of the class Clostridia.

4. A method for detecting a biomarker, comprising detecting the biomarker according to claim 1 in a sample obtained from a subject.

5. A method of collecting data for determining a stress level experienced by a subject, comprising the detection method according to claim 4.

6. A kit for determining the stress level experienced by a subject, comprising means for detecting the biomarker of claim 1.

7. A biomarker for evaluating the effect of an antidepressant in a subject, the biomarker being bacterial sialidase activity in a sample obtained from the subject.

8. The biomarker of claim 7, wherein the sample is feces.

9. The biomarker of claim 7, wherein the bacteria comprises bacteria of the class Clostridia.

10. A method for detecting a biomarker, comprising detecting the biomarker according to claim 7 in a sample obtained from a subject.

11. A method for collecting data for evaluating the effect of an antidepressant in a subject, comprising the detection method according to claim 10.

12. A kit for assessing the efficacy of an antidepressant in a subject comprising means for detecting the biomarker of claim 7.

13. A biomarker for determining the stress level experienced by a subject, the biomarker being the composition of bacterial species in a bacterial population having sialic acid in a sample obtained from the subject.

14. The biomarker according to claim 13, wherein the bacterial species composition in a bacterial population having sialic acid is the content of bacteria of the class Clostridium in a bacterial population having sialic acid.

15. The biomarker of claim 13, wherein the sample is feces.

16. A method for detecting a biomarker, comprising detecting the biomarker according to claim 13 in a sample taken from a subject.

17. A method of collecting data for determining a stress level experienced by a subject, comprising the detection method of claim 16.

18. A kit for determining the level of stress experienced by a subject, comprising means for detecting the biomarker of claim 13.

Citation Information

Patent Citations

  • Examination method and examination kit of depression by biomarker

    JP2017000063A

  • Method for predicting presence of affection of depression which emerges in person who is less than 50 years old

    JP2019193578A

  • Biomarker for diagnosing depression and use of said biomarker

    WO2017082103A1

  • Novel prebiotics

    JP2010531141A

  • Depression biomarker

    JP2024001864A